<html><head></head><body><h1>Co-trimoxazole</h1><p class="drug-subtitle"><b>Class:</b> Sulfonamides<br/>
- Antiprotozoal Agents<br/>
<b>VA Class:</b> AM900<br/>
<b>CAS Number:</b> 8064-90-2<br/>
<b>Brands:</b> Bactrim, Bactrim DS, Septra, Septra DS, Sulfatrim</p><ul class="ddc-anchor-links"><li>Uses</li>
<li>Dosage</li>
<li>Cautions</li>
<li>Interactions</li>
<li>Pharmacokinetics</li>
<li>Patient advice</li>
<li>Preparations</li>
<li>FAQ</li></ul><h2>Introduction</h2><p>Antibacterial; fixed combination of sulfamethoxazole (intermediate-acting sulfonamide) and trimethoprim; both sulfamethoxazole and trimethoprim are folate-antagonist anti-infectives.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="uses">Uses for Co-trimoxazole</h2><h3>Acute Otitis Media</h3><p>Treatment of acute otitis media (AOM) in adults† and children caused by susceptible <i>Streptococcus pneumoniae</i> or <i>Haemophilus influenzae</i>&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;186&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;272&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;273&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;274&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;278&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; when the clinician makes the judgment that the drug offers some advantage over use of a single anti-infective.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;186&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Not a drug of first choice; considered an alternative for treatment of AOM, especially for those with type I penicillin hypersensitivity.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;321&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Because amoxicillin-resistant <i>S. pneumoniae</i> frequently are resistant to co-trimoxazole, the drug may not be effective in patients with AOM who fail to respond to amoxicillin.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;302&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;321&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Data are limited regarding safety of repeated use of co-trimoxazole in pediatric patients &lt;2 years of age; the drug should not be administered prophylactically or for prolonged periods for treatment of AOM in any age group.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;186&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>GI Infections</h3><p>Treatment of travelers’ diarrhea caused by susceptible enterotoxigenic <i>Escherichia coli</i>.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;112&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;159&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;181&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;182&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;186&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;242&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;256&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Replacement therapy with oral fluids and electrolytes may be sufficient for mild to moderate disease;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;115&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;159&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;180&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;181&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;242&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;256&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;257&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; those who develop diarrhea with ≥3 loose stools in an 8-hour period (especially if associated with nausea, vomiting, abdominal cramps, fever, or blood in the stools) may benefit from short-term anti-infectives.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;114&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;115&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;159&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;180&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;242&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;259&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;306&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Fluoroquinolones (ciprofloxacin, levofloxacin, norfloxacin, ofloxacin) usually drugs of choice when treatment indicated;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;159&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;180&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;242&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;306&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; co-trimoxazole also has been recommended as an alternative when fluoroquinolones cannot be used (e.g., in children).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;159&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;242&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;306&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Prevention of travelers’ diarrhea† in individuals traveling forrelatively short periods to areas where enterotoxigenic <i>E. coli</i> and other causative bacterial pathogens (e.g., <i>Shigella</i>) are known to be susceptible to the drug.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;113&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;159&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;242&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; CDC and others do not recommend anti-infective prophylaxis in most individuals traveling to areas of risk;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;114&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;159&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;180&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;193&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;242&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;256&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;257&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;280&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; the principal preventive measures are prudent dietary practices.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;114&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;159&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;256&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;257&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; If prophylaxis is used (e.g., in immunocompromised individuals such as those with HIV infection), a fluoroquinolone (ciprofloxacin, levofloxacin, ofloxacin, norfloxacin) is preferred.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;159&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;180&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Resistance to co-trimoxazole is common in many tropical areas.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;159&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Treatment of enteritis caused by susceptible <i>Shigella flexneri</i> or <i>S. sonnei</i> when anti-infectives are indicated.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;121&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;186&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Treatment of dysentery caused by enteroinvasive <i>E. coli</i>† (EIEC).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; AAP suggests that an oral anti-infective (e.g., co-trimoxazole, azithromycin, ciprofloxacin) can be used if the causative organism is susceptible.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Treatment of diarrhea caused by enterotoxigenic <i>E. coli</i>† (ETEC) in travelers to resource-limited countries.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Optimal therapy not established, but AAP suggests that use of co-trimoxazole, azithromycin, or ciprofloxacin be considered if diarrhea is severe or intractable and if in vitro testing indicates the causative organism is susceptible.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; A parenteral regimen should be used if systemic infection is suspected.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Role of anti-infectives in treatment of hemorrhagic colitis caused by shiga toxin-producing <i>E. coli</i>† (STEC; formerly known as enterohemorrhagic <i>E. coli</i>) is unclear; most experts would not recommend use of anti-infectives in children with enteritis caused by <i>E. coli</i> 0157:H7.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Treatment of GI infections caused by <i>Yersinia enterocolitica</i>† or <i>Y. pseudotuberculosis</i>†.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;121&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;d&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; These infections usually are self-limited, but IDSA, AAP, and others recommend anti-infectives for severe infections, when septicemia or other invasive disease occurs, and in immunocompromised patients.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;d&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Other than decreasing the duration of fecal excretion of the organism, a clinical benefit of anti-infectives in management of enterocolitis, pseudoappendicitis syndrome, or mesenteric adenitis caused by <i>Yersinia</i> has not been established.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Respiratory Tract Infections</h3><p>Treatment of acute exacerbation of chronic bronchitis caused by susceptible <i>S. pneumoniae</i> or <i>H. influenzae</i>&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; when the clinician makes the judgment that the drug offers some advantage over use of a single anti-infective.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;186&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>A drug of choice for treatment of upper respiratory tract infections and bronchitis caused by <i>H. influenzae</i>;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;121&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; an alternative to penicillin G or penicillin V for treatment of respiratory tract infections caused by <i>S. pneumoniae</i>.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;121&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Alternative for treatment of infections caused by <i>Legionella micdadei</i>† (<i>L. pittsburgensis</i>) or <i>L. pneumophila</i>†.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;121&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Urinary Tract Infections (UTIs)</h3><p>Treatment of UTIs caused by susceptible <i>E. coli</i>, <i>Klebsiella</i>, <i>Enterobacter</i>, <i>Morganella morganii</i>, <i>Proteus mirabilis</i>, or <i>P. vulgaris</i>.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;186&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; A drug of choice for empiric treatment of acute uncomplicated UTIs.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;121&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;163&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Brucellosis</h3><p>Treatment of brucellosis†; alternative when tetracyclines are contraindicated (e.g., children).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;121&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Used alone or in conjunction with other anti-infectives (e.g., streptomycin or gentamicin and/or rifampin),&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;121&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; especially for severe infections or when there are complications (e.g., endocarditis, meningitis, osteomyelitis).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Burkholderia Infections</h3><p>Treatment of infections caused by <i>Burkholderia cepacia</i>†.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;121&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Co-trimoxazole considered drug of choice; ceftazidime, chloramphenicol, or imipenem are alternatives.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;121&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Treatment of melioidosis† caused by susceptible <i>B. pseudomallei</i>; used in multiple-drug regimen with chloramphenicol and doxycycline.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;121&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Ceftazidime or imipenem monotherapy may be preferred.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;121&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; <i>B. pseudomallei</i> is difficult to eradicate and relapse of melioidosis is common.</p><h3>Cholera</h3><p>Treatment of cholera† caused by <i>Vibrio cholerae</i>.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;121&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;231&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Alternative to tetracyclines; used as an adjunct to fluid and electrolyte replacement in moderate to severe disease.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;121&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;231&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Cyclospora Infections</h3><p>Treatment of infections caused by <i>Cyclospora cayetanensis</i>†.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;119&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;159&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;320&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; The drug of choice.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;119&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;159&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Granuloma Inguinale (Donovanosis)</h3><p>Treatment of granuloma inguinale (donovanosis) caused by <i>Calymmatobacterium granulomatis</i>†.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;116&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;121&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; CDC recommends doxycycline or co-trimoxazole.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;116&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Isosporiasis</h3><p>Treatment of isosporiasis† caused by <i>Isospora belli</i>.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;119&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;120&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; The drug of choice.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;119&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Listeria Infections</h3><p>Treatment of infections caused by <i>Listeria monocytogenes</i>†;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;121&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;232&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;233&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;234&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;235&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;236&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;237&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; a preferred alternative to ampicillin in penicillin-allergic patients.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;118&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;121&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Mycobacterial Infections</h3><p>Treatment of cutaneous infections caused by <i>Mycobacterium marinum</i>†;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;121&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;e&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; alternative to minocycline.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;121&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Nocardia Infections</h3><p>Treatment of infections caused by <i>Nocardia</i>†, including <i>N. asteroides, N. brasiliensis</i>, and <i>N. caviae</i>.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;121&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Drugs of choice are co-trimoxazole&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;121&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; or a sulfonamide alone (e.g., sulfisoxazole, sulfamethoxazole).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Pertussis</h3><p>Treatment of the catarrhal stage of pertussis† to potentially ameliorate the disease and reduce its communicability.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;121&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;164&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;165&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;166&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;168&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;169&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Recommended by CDC, AAP, and others as an alternative to erythromycin.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;121&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;164&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Prevention of pertussis† in household and other close contacts (e.g., day-care facility attendees) of patients with the disease.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;164&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;165&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;166&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;167&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;168&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;255&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Alternative to erythromycin.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;164&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;165&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;166&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;167&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;168&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;255&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Plague</h3><p>Has been used for postexposure prophylaxis of plague†.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;159&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;283&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Although recommended by CDC and others for such prophylaxis in infants and children &lt;8 years of age,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;159&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;283&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; efficacy of the drug for prevention of plague is unknown.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Most experts (e.g., CDC, AAP, the US Working Group on Civilian Biodefense, US Army Medical Research Institute of Infectious Diseases) recommend oral ciprofloxacin or doxycycline for postexposure prophylaxis in adults and most children.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;309&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;310&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Postexposure prophylaxis recommended after high-risk exposures to plague, including close exposure to individuals with naturally occurring plague, during unprotected travel in active epizootic or epidemic areas, or laboratory exposure to viable <i>Yersinia pestis</i>.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;159&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;283&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;309&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;310&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Has been used for treatment of plague†, but appears to be less effective than other anti-infectives used for treatment of the disease (e.g., streptomycin, gentamicin, tetracycline, doxycycline, chloramphenicol).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;309&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;311&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Because of lack of efficacy, some experts state that co-trimoxazole should not be used for the treatment of pneumonic plague.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;309&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Pneumocystis jiroveci (Pneumocystis carinii) Pneumonia</h3><p>Treatment of <i>Pneumocystis jiroveci</i> (formerly <i>Pneumocystis carinii</i>) pneumonia (PCP).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;119&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;186&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Initial drug of choice for most patients with PCP,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;119&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;170&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; including HIV-infected individuals.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;100&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;104&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;148&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;149&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;150&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;151&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;152&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;153&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;170&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;241&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Prevention of initial episodes of PCP (primary prophylaxis) in immunocompromised individuals at increased risk, including HIV-infected individuals.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;119&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;151&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;155&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;156&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;157&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;186&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;199&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;202&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;203&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;227&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;228&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;240&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;241&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;261&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;262&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;280&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Drug of choice.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;119&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;261&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;262&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; up to 14</p><p>Long-term suppressive or chronic maintenance therapy (secondary prophylaxis) to prevent recurrence following an initial PCP episode in immunocompromised patients, including HIV-infected individuals.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;119&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;199&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;202&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;203&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;227&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;228&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;241&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;262&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;280&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Drug of choice.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;119&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;280&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Toxoplasmosis</h3><p>Prevention of toxoplasmosis† encephalitis (primary prophylaxis) in HIV-infected adults, adolescents, and children who are seropositive for <i>Toxoplasma</i> IgG antibody.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;119&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;280&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Drug of choice.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;280&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Not recommended for long-term suppressive or chronic maintenance therapy (secondary prophylaxis) to prevent recurrence of toxoplasmosis encephalitis; regimen of choice for secondary prophylaxis of toxoplasmosis is sulfadiazine and pyrimethamine (with leucovorin).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;280&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Typhoid Fever and Other Salmonella Infections</h3><p>Alternative for treatment of typhoid fever† (enteric fever) caused by susceptible <i>Salmonella typhi</i>.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;121&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Drugs of choice are fluoroquinolones and third generation cephalosporins (e.g., ceftriaxone, cefotaxime);&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;121&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; consider that multidrug-resistant strains of <i>S. typhi</i> (strains resistant to ampicillin, amoxicillin, chloramphenicol, and/or co-trimoxazole) reported with increasing frequency.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;121&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Alternative for treatment of gastroenteritis caused by nontyphoidal <i>Salmonella</i>†.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;121&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Wegener’s Granulomatosis</h3><p>Treatment of Wegener’s granulomatosis†.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;122&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;123&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;133&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;146&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;147&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;207&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;c&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Effect on long-term morbidity and mortality unclear, but may prevent relapse and reduce need for cytotoxic (e.g., cyclophosphamide) and corticosteroid therapy in some patients.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;122&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;123&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;133&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;146&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;147&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;207&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;c&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Whipple’s Disease</h3><p>Treatment of Whipple’s disease† caused by <i>Tropheryma whippelii</i>.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;121&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Alternative or follow-up to penicillin G.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;121&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="dosage">Co-trimoxazole Dosage and Administration</h2><h3>Administration</h3><p>Administer orally&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; or by IV infusion.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Do <i>not</i> administer by rapid IV infusion or injection&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; and do <i>not</i> administer IM.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>An adequate fluid intake should be maintained during co-trimoxazole therapy to prevent crystalluria and stone formation.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>For solution and drug compatibility information, see Compatibility under Stability.</p><p>Co-trimoxazole concentrate for injection <i>must</i> be diluted prior to IV infusion.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Each 5 mL of the concentrate for injection containing 80 mg of trimethoprim should be added to 125 mL of 5% dextrose in water.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; In patients in whom fluid intake is restricted, each 5 mL of the concentrate may be added to 75 mL of 5% dextrose in water.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>IV solutions should be infused over a period of 60–90 minutes.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Dosage</h3><p>Available as fixed combination containing sulfamethoxazole and trimethoprim; dosage expressed as both the sulfamethoxazole and trimethoprim content or as the trimethoprim content.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Children ≥2 months of age: 8 mg/kg of trimethoprim and 40 mg/kg of sulfamethoxazole daily in 2 divided doses every 12 hours.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Usual duration is 10 days.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Children ≥2 months of age: 8 mg/kg of trimethoprim and 40 mg/kg of sulfamethoxazole daily in 2 divided doses every 12 hours.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Usual duration is 5 days.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Children ≥2 months of age: 8–10 mg/kg of trimethoprim daily (as co-trimoxazole) in 2–4 equally divided doses given for 5 days.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Children ≥2 months of age: 8 mg/kg of trimethoprim and 40 mg/kg of sulfamethoxazole daily in 2 divided doses every 12 hours.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Usual duration is 10 days.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Children ≥2 months of age: 8–10 mg/kg of trimethoprim daily (as co-trimoxazole) in 2–4 equally divided doses given for up to 14 days.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>10 mg/kg daily (up to 480 mg daily) of trimethoprim (as co-trimoxazole) in 2 divided doses for 4–6 weeks.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>4–5 mg/kg of trimethoprim (as co-trimoxazole) twice daily given for 3 days.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;283&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>5 mg/kg of trimethoprim and 25 mg/kg of sulfamethoxazole twice daily given for 7–10 days.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;119&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; HIV-infected patients may require higher dosage and longer treatment.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;119&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Adolescents: 160 mg of trimethoprim and 800 mg of sulfamethoxazole twice daily given for ≥3 weeks or until all lesions have healed completely;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;116&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; consider adding IV aminoglycoside (e.g., gentamicin) if improvement is not evident within the first few days of therapy and in HIV-infected patients.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;116&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Relapse can occur 6–18 months after apparently effective treatment.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;116&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>5 mg/kg of trimethoprim and 25 mg/kg of sulfamethoxazole twice daily.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;119&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Usual duration of treatment is 10 days; higher dosage or more prolonged treatment necessary in immunocompromised patients.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;119&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>8 mg/kg of trimethoprim and 40 mg/kg of sulfamethoxazole daily in 2 divided doses.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;164&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Usual duration is 14 days for treatment or prevention.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;164&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;222&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;223&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;224&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;225&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;226&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Children ≥2 months of age: 320–640 mg of trimethoprim (as co-trimoxazole) daily in 2 divided doses given for 7 days.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;283&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Alternatively, 8 mg/kg daily of trimethoprim (as co-trimoxazole) in 2 divided doses given for 7 days.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;283&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Children ≥2 months of age: 15–20 mg/kg of trimethoprim and 75–100 mg/kg of sulfamethoxazole daily in 3 or 4 divided doses.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;119&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Usual duration is 14–21 days.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;119&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Children ≥2 months of age: 15–20 mg/kg of trimethoprim daily (as co-trimoxazole) in 3 or 4 equally divided doses.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;119&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Usual duration is 14–21 days.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;119&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>150 mg/m<sup>2</sup> of trimethoprim and 750 mg/m<sup>2</sup> of sulfamethoxazole daily in 2 divided doses given on 3 consecutive days each week.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;119&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;186&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;280&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Total daily dose should not exceed 320 mg of trimethoprim and 1.6 g of sulfamethoxazole.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Alternatively, 150 mg/m<sup>2</sup> of trimethoprim and 750 mg/m<sup>2</sup> of sulfamethoxazole can be administered as a single dose 3 times each week on consecutive days, in 2 divided doses daily 7 days each week, or in 2 divided daily doses given 3 times each week on alternate days.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;280&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>CDC, USPHS/IDSA, AAP, and others recommend that primary prophylaxis be initiated in all infants born to HIV-infected women starting at 4–6 weeks of age, regardless of their CD4<sup>+</sup> T-cell count.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;280&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;282&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Infants who are first identified as being HIV-exposed after 6 weeks of age should receive primary prophylaxis beginning at the time of identification.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;282&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Primary prophylaxis should be continued until 12 months of age in all HIV-infected infants and infants whose infection status has not yet been determined;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;280&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;282&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; it can be discontinued in those found not to be HIV-infected.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;280&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;282&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>The need for subsequent prophylaxis should be based on age-specific CD4<sup>+</sup> T-cell count thresholds.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;280&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;282&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; In HIV-infected children 1–5 years of age, primary prophylaxis should be initiated if CD4<sup>+</sup> T-cell counts are &lt;500/mm<sup>3</sup> or CD4<sup>+</sup> percentage is &lt;15%.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;280&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;282&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; In HIV-infected children 6–12 years of age, primary prophylaxis should be initiated if CD4<sup>+</sup> T-cell counts are &lt;200/mm<sup>3</sup> or CD4<sup>+</sup> percentage is &lt;15%.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;280&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;282&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>The safety of discontinuing prophylaxis in HIV-infected children receiving potent antiretroviral therapy has not been extensively studied.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;280&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>150 mg/m<sup>2</sup> of trimethoprim and 750 mg/m<sup>2</sup> of sulfamethoxazole daily in 2 divided doses given on 3 consecutive days each week.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;119&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;186&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;280&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Total daily dose should not exceed 320 mg of trimethoprim and 1.6 g of sulfamethoxazole.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Alternatively, 150 mg/m<sup>2</sup> of trimethoprim and 750 mg/m<sup>2</sup> of sulfamethoxazole can be administered as a single daily dose given for 3 consecutive days each week, in 2 divided doses daily, or in 2 divided daily doses given 3 times a week on alternate days.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;280&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>The safety of discontinuing secondary prophylaxis in HIV-infected children receiving potent antiretroviral therapy has not been extensively studied.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;280&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Children who have a history of PCP should receive life-long suppressive therapy to prevent recurrence.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;280&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Dosage for primary or secondary prophylaxis against <i>P. jiroveci</i> pneumonia in adolescents and criteria for initiation or discontinuance of such prophylaxis in this age group are the same as those recommended for adults.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;280&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Adult Dosage under Dosage and Administration.)</p><p>150 mg/m<sup>2</sup> of trimethoprim and 750 mg/m<sup>2</sup> of sulfamethoxazole daily in 2 divided doses.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;280&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>The safety of discontinuing toxoplasmosis prophylaxis in HIV-infected children receiving potent antiretroviral therapy has not been extensively studied.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;280&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Dosage for primary prophylaxis against toxoplasmosis in adolescents and criteria for initiation or discontinuance of such prophylaxis in this age group are the same as those recommended for adults.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;280&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Adult Dosage under Dosage and Administration.)</p><p>160 mg of trimethoprim and 800 mg of sulfamethoxazole every 12 hours given for 3–5 days.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;112&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;183&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;186&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;242&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;256&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;257&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;306&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; A single 320-mg dose of trimethoprim (as co-trimoxazole) also has been used.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;242&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;306&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>160 mg of trimethoprim and 800 mg of sulfamethoxazole once daily during the period of risk.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;256&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;257&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Use of anti-infectives for prevention of travelers’ diarrhea generally is discouraged.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;112&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;180&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;186&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;242&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;256&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;257&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;306&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>160 mg of trimethoprim and 800 mg of sulfamethoxazole every 12 hours given for 5 days.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>8–10 mg/kg of trimethoprim daily (as co-trimoxazole) in 2–4 equally divided doses given for 5 days.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>160 mg of trimethoprim and 800 mg of sulfamethoxazole every 12 hours given for 14 days.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>160 mg of trimethoprim and 800 mg of sulfamethoxazole every 12 hours.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Usual duration of treatment is 10–14 days.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; A 3-day regimen may be effective for acute, uncomplicated cystitis in women.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;121&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;163&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>8–10 mg/kg of trimethoprim daily (as co-trimoxazole) in 2–4 equally divided doses given for up to 14 days.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>160 mg of trimethoprim and 800 mg of sulfamethoxazole every 12 hours given for 3 days.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;231&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>160 mg of trimethoprim and 800 mg of sulfamethoxazole twice daily given for 7–10 days.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;119&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; HIV-infected patients may require higher dosage and longer-term treatment.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;119&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>160 mg of trimethoprim and 800 mg of sulfamethoxazole twice daily given for ≥3 weeks or until all lesions have healed completely;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;116&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; consider adding IV aminoglycoside (e.g., gentamicin) if improvement is not evident within the first few days of therapy and in HIV-infected patients.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;116&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Relapse can occur 6–18 months after apparently effective treatment.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;116&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>160 mg of trimethoprim and 800 mg of sulfamethoxazole twice daily.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;119&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Usual duration of treatment is 10 days; higher dosage or more prolonged treatment necessary in immunocompromised patients.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;119&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>160 mg of trimethoprim and 800 mg of sulfamethoxazole twice daily given for ≥3 months recommended by ATS for treatment of cutaneous infections.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;c&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; A minimum of 4–6 weeks of treatment usually is necessary to determine whether the infection is responding.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;c&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>320 mg of trimethoprim (as co-trimoxazole) daily in 2 divided doses.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;164&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;166&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;168&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Usual duration is 14 days for treatment or prevention.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;164&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;222&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;223&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;224&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;225&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;226&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;286&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>15–20 mg/kg of trimethoprim and 75–100 mg/kg of sulfamethoxazole daily in 3 or 4 divided doses.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;119&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;170&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;186&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Usual duration is 14–21 days.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;119&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>15–20 mg/kg of trimethoprim daily in 3 or 4 equally divided doses every 6 or 8 hours given for up to 14 days.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Some clinicians recommend 15 mg/kg of trimethoprim and 75 mg/kg of sulfamethoxazole daily in 3 or 4 divided doses for 14–21 days.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;119&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>160 mg of trimethoprim and 800 mg of sulfamethoxazole once daily.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;119&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;186&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;227&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;240&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;241&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;243&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;280&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Alternatively, 80 mg of trimethoprim and 400 mg of sulfamethoxazole can be given once daily.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;119&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;280&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Initiate primary prophylaxis in patients with CD4<sup>+</sup> T-cell counts &lt;200/mm<sup>3</sup> or a history of oropharyngeal candidiasis.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;280&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Also consider primary prophylaxis if CD4<sup>+</sup> T-cell percentage is &lt;14% or there is a history of an AIDS-defining illness.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;280&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Primary prophylaxis can be discontinued in adults and adolescents responding to potent antiretroviral therapy who have a sustained (≥3 months) increase in CD4<sup>+</sup> T-cell counts from &lt;200/mm<sup>3</sup> to &gt;200/mm<sup>3</sup>.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;199&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;280&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;281&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;287&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;312&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;313&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;314&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;315&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;316&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; However, it should be restarted if CD4<sup>+</sup> T-cell count decreases to &lt;200/mm<sup>3</sup>.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;280&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>160 mg of trimethoprim and 800 mg of sulfamethoxazole once daily.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;119&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;280&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Alternatively, 80 mg of trimethoprim and 400 mg of sulfamethoxazole can be given once daily.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;119&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;280&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Initiate long-term suppressive therapy or chronic maintenance therapy (secondary prophylaxis) in those with a history of <i>P. jiroveci</i> pneumonia to prevent recurrence.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;280&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Discontinuance of secondary prophylaxis is recommended in those who have a sustained (≥3 months) increase in CD4<sup>+</sup> T-cell counts to &gt;200/mm<sup>3</sup> since such prophylaxis appears to add little benefit in terms of disease prevention and discontinuance reduces the medication burden, the potential for toxicity, drug interactions, selection of drug-resistant pathogens, and cost.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;280&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Reinitiate secondary prophylaxis if CD4<sup>+</sup> T-cell count decreases to &lt;200/mm<sup>3</sup> or if <i>P. jiroveci</i> pneumonia recurs at a CD4<sup>+</sup> T-cell &gt;200/mm<sup>3</sup>.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;280&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; It probably is prudent to continue secondary prophylaxis for life in those who had <i>P. jiroveci</i> episodes when they had CD4<sup>+</sup> T-cell counts &gt;200/mm<sup>3</sup>.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;280&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>160 mg of trimethoprim and 800 mg of sulfamethoxazole once daily.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;280&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Alternatively, 80 mg of trimethoprim and 400 mg of sulfamethoxazole may be used.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;280&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Initiate primary prophylaxis against toxoplasmosis in HIV-infected adults and adolescents who are seropositive for <i>Toxoplasma</i> IgG antibody and have CD4<sup>+</sup> T-cell counts &lt;100/mm<sup>3</sup>.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;280&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Consideration can be given to discontinuing primary prophylaxis in adults and adolescents who have a sustained (≥3 months) increase in CD4<sup>+</sup> T-cell counts to &gt;200/mm<sup>3</sup> since such prophylaxis appears to add little benefit in terms of disease prevention for toxoplasmosis, and discontinuance reduces the pill burden, the potential for toxicity, drug interactions, selection of drug-resistant pathogens, and cost.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;280&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Reinitiate primary prophylaxis against toxoplasmosis if CD4<sup>+</sup> T-cell count decreases to &lt;100–200/mm<sup>3</sup>.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;280&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>160 mg of trimethoprim and 800 mg of sulfamethoxazole twice daily.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;c&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Special Populations</h3><p>In patients with Cl<sub>cr</sub> 15–30 mL/minute, use 50% of usual dosage.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Use not recommended in those with Cl<sub>cr</sub> &lt;15 mL/minute.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>No dosage adjustments except those related to renal impairment.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Renal Impairment under Dosage and Administration.)</p><h2 class="ddc-anchor-offset" id="cautions">Cautions for Co-trimoxazole</h2><h3>Contraindications</h3><ul>
<li>
<p>Known hypersensitivity to sulfonamides or trimethoprim.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Documented megaloblastic anemia due to folate deficiency.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Children &lt;2 months of age, pregnant women at term, and nursing women.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
</ul><p>Known hypersensitivity to sulfonamides or trimethoprim.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Documented megaloblastic anemia due to folate deficiency.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Children &lt;2 months of age, pregnant women at term, and nursing women.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Warnings/Precautions</h3><p>Severe (sometimes fatal) reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia, and other blood dyscrasias, have been reported with sulfonamides.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Rash, sore throat, fever, arthralgia, pallor, purpura, or jaundice may be early indications of serious reactions.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Discontinue co-trimoxazole at the first appearance of rash or any sign of adverse reactions.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Possible emergence and overgrowth of nonsusceptible bacteria or fungi.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Institute appropriate therapy if superinfection occurs.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Treatment with anti-infectives may permit overgrowth of clostridia.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Consider <i>Clostridium difficile</i>-associated diarrhea and colitis (antibiotic-associated pseudomembranous colitis) if diarrhea develops and manage accordingly.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Some mild cases of <i>C. difficile</i>-associated diarrhea and colitis may respond to discontinuance alone.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Manage moderate to severe cases with fluid, electrolyte, and protein supplementation; appropriate anti-infective therapy (e.g., oral metronidazole or vancomycin) recommended if colitis is severe.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Cough, shortness of breath, and pulmonary infiltrates are hypersensitivity reactions of the respiratory tact that have been reported with sulfonamides.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Use with caution in patients with severe allergy or bronchial asthma.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Concentrate for injection contains a sulfite, which may cause allergic-type reactions (including anaphylaxis and life-threatening or less severe asthmatic episodes) in certain susceptible individuals.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Hemolysis may occur in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency; this effect may be dose-related.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Use with caution in patient with possible folate deficiency (e.g., geriatric patients, chronic alcoholics, patients receiving anticonvulsant therapy, patients with malabsorption syndrome, patients with malnutrition).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>HIV-infected patients with <i>Pneumocystis jiroveci</i> pneumonia may have an increased incidence of adverse effects during co-trimoxazole therapy (particularly rash, fever, leukopenia, increased liver enzymes) compared with HIV-seronegative patients.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; The incidence of hyperkalemia and hyponatremia also may be increased in HIV-infected patients.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Adverse effects generally are less severe in those receiving co-trimoxazole for prophylaxis rather than treatment.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>A history of mild intolerance to co-trimoxazole in HIV-infected patients does not appear to predict intolerance to subsequent use of the drug for secondary prophylaxis.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; However, use of the drug should be reevaluated in patients who develop rash or any sign of adverse reaction.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Concomitant use of leucovorin and co-trimoxazole for acute treatment of <i>P. jiroveci</i> pneumonia in HIV-infected patients has been associated with increased rates of treatment failure and morbidity.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Perform CBCs frequently during co-trimoxazole therapy; discontinue the drug if a significant reduction in any formed blood element occurs.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Perform urinalysis with careful microscopic examination and renal function tests during co-trimoxazole therapy, especially in patients with impaired renal function.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>To reduce development of drug-resistant bacteria and maintain effectiveness of co-trimoxazole and other antibacterials, use only for treatment or prevention of infections proven or strongly suspected to be caused by susceptible bacteria.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>When selecting or modifying anti-infective therapy, use results of culture and in vitro susceptibility testing.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Because <i>S. pyogenes</i> (group A β-hemolytic streptococci) may not be eradicated by co-trimoxazole, do not use the drug for treatment of infections caused by this organism since it cannot prevent sequelae such as rheumatic fever.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Category C.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Because sulfonamides may cause kernicterus in neonates, co-trimoxazole is contraindicated in pregnant women at term.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Both sulfamethoxazole and trimethoprim distributed into milk.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Co-trimoxazole contraindicated in nursing women.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Safety and efficacy not established in children &lt;2 months of age.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Geriatric patients may be at increased risk of severe adverse reactions, particularly if they have impaired hepatic and/or renal function or are receiving concomitant drug therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>The most frequent adverse reactions in geriatric patients are severe skin reactions, generalized bone marrow suppression, or a specific decrease in platelets (with or without purpura).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Those receiving concurrent therapy with a diuretic (principally thiazides) are at increased risk of thrombocytopenia with purpura.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Dosage adjustments are necessary based on age-related decreases in renal function.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Use with caution in patients with impaired hepatic function.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Use reduced dosage in patients with Cl<sub>cr</sub> 15–30 mL/minute.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Do not use in patients with Cl<sub>cr</sub> &lt;15 mL/minute.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Common Adverse Effects</h3><p>GI effects (nausea, vomiting, anorexia); dermatologic and sensitivity reactions (rash, urticaria).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="interactions">Interactions for Co-trimoxazole</h2><h3>Specific Drugs and Laboratory Tests</h3><p>Drug or Test</p><p>Interaction</p><p>Comments</p><p>Amantadine</p><p>Toxic delirium reported in an individual who received amantadine and co-trimoxazole concomitantly&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;186&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Antidepressants, tricyclics</p><p>Possible decreased efficacy of the tricyclic antidepressant&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;186&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Cyclosporine</p><p>Reversible nephrotoxicity reported in renal transplant recipients receiving cyclosporine and co-trimoxazole concomitantly&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;186&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Digoxin</p><p>Possible increased digoxin concentrations, especially in geriatric patients&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;186&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Monitor serum digoxin concentrations in patients receiving co-trimoxazole concomitantly&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;186&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Diuretics</p><p>Possible increased incidence of thrombocytopenia and purpura if certain diuretics (principally thiazides) are used concomitantly, especially in geriatric patients&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Hypoglycemic agents, oral</p><p>Possible potentiation of hypoglycemic effects&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;186&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Indomethacin</p><p>Possible increased sulfamethoxazole concentrations&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;186&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Methotrexate</p><p>Co-trimoxazole can displace methotrexate from plasma protein-binding sites resulting in increased free methotrexate concentrations&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Possible interference with serum methotrexate assays if competitive protein binding technique is used with a bacterial dihydrofolate reductase as the binding protein; interference does not occur if methotrexate is measured using radioimmunoassay&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Use caution if methotrexate and co-trimoxazole used concomitantly&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Phenytoin</p><p>Co-trimoxazole may inhibit metabolism and increase half-life of phenytoin&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;186&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Monitor for possible increased phenytoin effects&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;186&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Pyrimethamine</p><p>Megaloblastic anemia reported when co-trimoxazole used concomitantly with pyrimethamine dosages &gt;25 mg weekly (for malaria prophylaxis)&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;186&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Tests for creatinine</p><p>Possible interference with Jaffe alkaline picrate assay resulting in falsely elevated creatinine concentrations&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Warfarin</p><p>Possible inhibition of warfarin clearance and prolonged PT&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Monitor PT closely and adjust warfarin dosage if co-trimoxazole used concomitantly&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="pharmacokinetics">Co-trimoxazole Pharmacokinetics</h2><h3>Absorption</h3><p>Sulfamethoxazole and trimethoprim are rapidly and well absorbed from the GI tract following oral administration of the fixed combination preparation (co-trimoxazole).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Peak serum concentrations of both sulfamethoxazole and trimethoprim are attained within 1–4 hours.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Co-trimoxazole contains a 1:5 ratio of trimethoprim to sulfamethoxazole, but the trimethoprim:sulfamethoxazole ratio in serum after administration of the fixed-combination preparation is about 1:20 at steady-state.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Distribution</h3><p>Widely distributed into body tissues and fluids, including sputum, aqueous humor, middle ear fluid, bronchial secretions, prostatic fluid, vaginal fluid, and bile.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>In patients with uninflamed meninges, trimethoprim and sulfamethoxazole concentrations in CSF are about 50 and 40%, respectively, of concurrent serum concentrations.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Both sulfamethoxazole and trimethoprim readily cross the placenta and are distributed into milk.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Sulfamethoxazole is approximately 70% and trimethoprim is approximately 44% bound to plasma proteins.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Presence of sulfamethoxazole decreases protein binding of trimethoprim.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Elimination</h3><p>Both sulfamethoxazole and trimethoprim are metabolized in the liver.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Both sulfamethoxazole and trimethoprim are rapidly excreted in urine by glomerular filtration and active tubular secretion.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; In adults with normal renal function, approximately 45–85% of a sulfamethoxazole dose and 50–67% of a trimethoprim dose are excreted in urine.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Only small amounts of trimethoprim are excreted in feces via biliary elimination.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Serum half-lives of sulfamethoxazole and trimethoprim are approximately 10–13 and 8–11 hours, respectively, in adults with normal renal function.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Patients with impaired renal function: Half-lives of both sulfamethoxazole and trimethoprim may be prolonged.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>In adults with Cl<sub>cr</sub>≤10 mL/minute, serum half-life of trimethoprim may increase to &gt;26 hours.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; In adults with chronic renal failure, sulfamethoxazole half-life may be 3 times that in patients with normal renal function.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2>Stability</h2><h3>Storage</h3><p>15–25°C;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; protect from light.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>15–25°C;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; protect from light.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>5–25°C;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; do not refrigerate.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Following dilution in 125 or 100 mL of 5% dextrose in water, use within 6 or 4 hours, respectively.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; If diluted in 75 mL of 5% dextrose in water, use within 2 hours.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Compatibility</h3><p>For information on systemic interactions resulting from concomitant use, see Interactions.</p><p>Compatible</p><p>Dextrose 5% in sodium chloride 0.45%</p><p>Ringer’s injection, lactated</p><p>Sodium chloride 0.45%</p><p>Variable</p><p>Dextrose 5% in water</p><p>Sodium chloride 0.9%</p><p>Incompatible</p><p>Fluconazole</p><p>Linezolid</p><p>Verapamil HCl</p><p>Compatible</p><p>Acyclovir sodium</p><p>Aldesleukin</p><p>Allopurinol sodium</p><p>Amifostine</p><p>Amphotericin B cholesteryl sulfate complex</p><p>Anidulafungin</p><p>Atracurium besylate</p><p>Aztreonam</p><p>Bivalirudin</p><p>Ceftaroline fosamil</p><p>Cyclophosphamide</p><p>Dexmedetomidine HCl</p><p>Diltiazem HCl</p><p>Docetaxel</p><p>Doxorubicin HCl liposome injection</p><p>Enalaprilat</p><p>Esmolol HCl</p><p>Etoposide phosphate</p><p>Fenoldopam mesylate</p><p>Filgrastim</p><p>Fludarabine phosphate</p><p>Gallium nitrate</p><p>Gemcitabine HCl</p><p>Granisetron HCl</p><p>Hetastarch in lactated electrolyte injection (Hextend)</p><p>Hydromorphone HCl</p><p>Labetalol HCl</p><p>Lorazepam</p><p>Magnesium sulfate</p><p>Melphalan HCl</p><p>Meperidine HCl</p><p>Morphine sulfate</p><p>Nicardipine HCl</p><p>Pancuronium bromide</p><p>Pemetrexed disodium</p><p>Piperacillin sodium-tazobactam sodium</p><p>Remifentanil HCl</p><p>Sargramostim</p><p>Tacrolimus</p><p>Teniposide</p><p>Thiotepa</p><p>Vecuronium bromide</p><p>Zidovudine</p><p>Incompatible</p><p>Caspofungin acetate</p><p>Fluconazole</p><p>Midazolam HCl</p><p>Vinorelbine tartrate</p><p>Variable</p><p>Cisatracurium besylate</p><p>Foscarnet sodium</p><h2>Actions and Spectrum</h2><ul>
<li>
<p>A fixed combination of sulfamethoxazole and trimethoprim; both drugs are folate-antagonists and sequentially inhibit enzymes of the folic acid pathway in susceptible bacteria.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Sulfamethoxazole inhibits formation of dihydrofolic acid from <i>p</i>-aminobenzoic acid and trimethoprim inhibits formation of tetrahydrofolic acid (the metabolically active form of folic acid).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Sulfamethoxazole is bacteriostatic and trimethoprim usually is bactericidal; the fixed combination generally is bactericidal when synergism is achieved.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Susceptibility to trimethoprim is more critical to efficacy of co-trimoxazole than susceptibility to sulfamethoxazole.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Co-trimoxazole is active against many organisms resistant to sulfamethoxazole but susceptible to trimethoprim.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Spectrum of activity includes many gram-positive and -negative aerobic bacteria and some protozoa.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Inactive against most anaerobic bacteria and inactive against fungi and viruses.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Gram-positive aerobes: Active against <i>Staphylococcus aureus</i> (including penicillinase-producing strains), <i>Streptococcus pneumoniae</i>, <i>S. pyogenes</i> (group A β-hemolytic streptococci), and some strains of enterococci (e.g., <i>Enterococcus faecalis</i>).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Also active against <i>Nocardia</i>,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; but <i>Bacillus anthracis</i> may be resistant.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;307&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;308&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Gram-negative aerobes: Active against <i>Acinetobacter</i>, <i>Enterobacter</i>, <i>Escherichia coli</i>, <i>Klebsiella pneumoniae</i>, <i>Morganella morganii</i>, <i>Proteus mirabilis</i>, <i>Salmonella</i>, and <i>Shigella</i>.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Also active against <i>Haemophilus influenzae</i> (including ampicillin-resistant strains), <i>H. ducreyi</i>, and <i>Neisseria gonorrhoeae</i>.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; <i>Pseudomonas aeruginosa</i> is resistant.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Other organisms: Active in vitro and in vivo against <i>Pneumocystis jiroveci</i> (<i>Pneumocystis carinii</i>).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Most anaerobes, including <i>Bacteroides</i> and <i>Clostridium</i>, are resistant.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Resistance to co-trimoxazole has been reported in some Enterobacteriaceae and <i>H. influenzae</i>.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
</ul><p>A fixed combination of sulfamethoxazole and trimethoprim; both drugs are folate-antagonists and sequentially inhibit enzymes of the folic acid pathway in susceptible bacteria.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Sulfamethoxazole inhibits formation of dihydrofolic acid from <i>p</i>-aminobenzoic acid and trimethoprim inhibits formation of tetrahydrofolic acid (the metabolically active form of folic acid).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Sulfamethoxazole is bacteriostatic and trimethoprim usually is bactericidal; the fixed combination generally is bactericidal when synergism is achieved.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Susceptibility to trimethoprim is more critical to efficacy of co-trimoxazole than susceptibility to sulfamethoxazole.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Co-trimoxazole is active against many organisms resistant to sulfamethoxazole but susceptible to trimethoprim.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Spectrum of activity includes many gram-positive and -negative aerobic bacteria and some protozoa.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Inactive against most anaerobic bacteria and inactive against fungi and viruses.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Gram-positive aerobes: Active against <i>Staphylococcus aureus</i> (including penicillinase-producing strains), <i>Streptococcus pneumoniae</i>, <i>S. pyogenes</i> (group A β-hemolytic streptococci), and some strains of enterococci (e.g., <i>Enterococcus faecalis</i>).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Also active against <i>Nocardia</i>,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; but <i>Bacillus anthracis</i> may be resistant.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;307&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;308&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Gram-negative aerobes: Active against <i>Acinetobacter</i>, <i>Enterobacter</i>, <i>Escherichia coli</i>, <i>Klebsiella pneumoniae</i>, <i>Morganella morganii</i>, <i>Proteus mirabilis</i>, <i>Salmonella</i>, and <i>Shigella</i>.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Also active against <i>Haemophilus influenzae</i> (including ampicillin-resistant strains), <i>H. ducreyi</i>, and <i>Neisseria gonorrhoeae</i>.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; <i>Pseudomonas aeruginosa</i> is resistant.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Other organisms: Active in vitro and in vivo against <i>Pneumocystis jiroveci</i> (<i>Pneumocystis carinii</i>).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Most anaerobes, including <i>Bacteroides</i> and <i>Clostridium</i>, are resistant.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Resistance to co-trimoxazole has been reported in some Enterobacteriaceae and <i>H. influenzae</i>.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;b&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="patient-advice">Advice to Patients</h2><ul>
<li>
<p>Importance of completing full course of therapy, even if feeling better after a few days.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Advise patients to maintain an adequate fluid intake to prevent crystalluria and stone formation.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of discontinuing drug and informing clinician if rash or any sign of adverse reaction (sore throat, fever, arthralgia, pallor, purpura, jaundice) occurs.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of informing clinicians of existing or contemplated therapy, including prescription and OTC drugs, and any concomitant illnesses.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of women informing clinicians if they are or plan to become pregnant or to breast-feed.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of advising patients of other important precautionary information.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Cautions.)</p>
</li>
</ul><p>Importance of completing full course of therapy, even if feeling better after a few days.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Advise patients to maintain an adequate fluid intake to prevent crystalluria and stone formation.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of discontinuing drug and informing clinician if rash or any sign of adverse reaction (sore throat, fever, arthralgia, pallor, purpura, jaundice) occurs.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of informing clinicians of existing or contemplated therapy, including prescription and OTC drugs, and any concomitant illnesses.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of women informing clinicians if they are or plan to become pregnant or to breast-feed.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of advising patients of other important precautionary information.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Cautions.)</p><h2 class="ddc-anchor-offset" id="preparations">Preparations</h2><p><i>Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.</i></p><p><i>Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.</i></p><p>* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name</p><p>Routes</p><p>Dosage Forms</p><p>Strengths</p><p>Brand Names</p><p>Manufacturer</p><p>Oral</p><p>Suspension</p><p>Trimethoprim 40 mg/5 mL and Sulfamethoxazole 200 mg/5 mL*</p><p>Septra<sup></sup> <b>Suspension</b></p><p>Monarch</p><p>Septra<sup></sup> <b>Grape Suspension</b></p><p>Monarch</p><p>Sulfatrim<sup></sup> <b>Pediatric Suspension</b></p><p>Alpharma</p><p>Sulfatrim<sup></sup> <b>Suspension</b></p><p>Alpharma, United Research</p><p>Tablets</p><p>Trimethoprim 80 mg and Sulfamethoxazole 400 mg*</p><p>Bactrim<sup></sup> (scored)</p><p>Women First HealthCare</p><p>Septra<sup></sup> (scored)</p><p>Monarch</p><p>Sulfamethoxazole and Trimethoprim Tablets</p><p>Trimethoprim 160 mg and Sulfamethoxazole 800 mg*</p><p>Bactrim<sup></sup> DS</p><p>Women First HealthCare</p><p>Septra<sup></sup> DS (scored)</p><p>Monarch</p><p>Parenteral</p><p>For injection concentrate, for IV infusion</p><p>Trimethoprim 16 mg/mL and Sulfamethoxazole 80 mg/mL</p><p>Sulfamethoxazole and Trimethoprim Concentrate for Injection</p><p>AHFS<sup></sup> DI Essentials™. © Copyright 2021, Selected Revisions September 4, 2013. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.</p><p>† Use is not currently included in the labeling approved by the US Food and Drug Administration.</p><h2>References</h2><p>Only references cited for selected revisions after 1984 are available electronically.</p><p>100. Murray JF, Felton CP, Garay SM et al. Pulmonary complications of the acquired immunodeficiency syndrome. Report of a National Heart, Lung, and Blood Institute Workshop. <i>N Engl J Med</i>. 1984; 310:1682-9. http://www.ncbi.nlm.nih.gov/pubmed/6328301?dopt=AbstractPlus</p><p>101. Jaffe HS, Abrams DI, Ammann AJ et al. Complications of co-trimoxazole in treatment of AIDS-associated Pneumocystis carinii pneumonia in homosexual men. <i>Lancet</i>. 1983; 2:1109-11. http://www.ncbi.nlm.nih.gov/pubmed/6138645?dopt=AbstractPlus</p><p>102. Gordin FM, Simon GL, Wofsy CB et al. Adverse reactions to trimethoprim-sulfamethoxazole in patients with acquired immunodeficiency syndrome. <i>Ann Intern Med</i>. 1984; 100:495-9. http://www.ncbi.nlm.nih.gov/pubmed/6230976?dopt=AbstractPlus</p><p>103. Kovacs JA, Hiemenz JW, Macher AM et al. <i>Pneumocystis carinii</i> pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. <i>Ann Intern Med</i>. 1984; 100:663-71. http://www.ncbi.nlm.nih.gov/pubmed/6231873?dopt=AbstractPlus</p><p>104. Wong B. Parasitic diseases in immunocompromised hosts. <i>Am J Med</i>. 1984; 76:479-86. http://www.ncbi.nlm.nih.gov/pubmed/6608268?dopt=AbstractPlus</p><p>105. Haverkos HW. Assessment of therapy for Pneumocystis carinii pneumonia: PCP Therapy Project Group. <i>Am J Med</i>. 1984; 76:501-8. http://www.ncbi.nlm.nih.gov/pubmed/6367458?dopt=AbstractPlus</p><p>106. Pesanti EL. In vitro effects of antiprotozoan drugs and immune serum on <i>Pneumocystis carinii</i>. <i>J Infect Dis</i>. 1980; 141:775-80. http://www.ncbi.nlm.nih.gov/pubmed/6156221?dopt=AbstractPlus</p><p>107. Pesanti EL, Cox C. Metabolic and synthetic activities of <i>Pneumocystis carinii</i> in vitro. <i>Infect Immun</i>. 1981; 34:908-14. http://www.ncbi.nlm.nih.gov/pubmed/6174453?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=350955&amp;blobtype=pdf</p><p>108. Pifer LL, Pifer DD, Woods DR. Biological profile and response to anti-pneumocystis agents of <i>Pneumocystis carinii</i> in cell culture. <i>Antimicrob Agents Chemother</i>. 1983; 24:674-8. http://www.ncbi.nlm.nih.gov/pubmed/6607029?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=185923&amp;blobtype=pdf</p><p>109. Small CB, Harris CA, Friedland GH et al. The treatment of <i>Pneumocystis carinii</i> pneumonia in the acquired immunodeficiency syndrome. <i>Arch Intern Med</i>. 1985; 145:837-40. http://www.ncbi.nlm.nih.gov/pubmed/3873229?dopt=AbstractPlus</p><p>110. Kluge RM, Spaulding DM, Spain AJ. Combination of pentamidine and trimethoprim-sulfamethoxazole in the therapy of <i>Pneumocystis carinii</i> pneumonia in rats. <i>Antimicrob Agents Chemother</i>. 1978; 13:975-8. http://www.ncbi.nlm.nih.gov/pubmed/307941?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=352374&amp;blobtype=pdf</p><p>111. Shelhamer JH, Ognibene FP, Macher AM et al. Persistence of <i>Pneumocystis carinii</i> in lung tissue of acquired immunodeficiency syndrome patients treated for pneumocystis pneumonia. <i>Am Rev Respir Dis</i>. 1984; 130:1161-5. http://www.ncbi.nlm.nih.gov/pubmed/6334462?dopt=AbstractPlus</p><p>112. DuPont HL, Reves RR, Galindo E et al. Treatment of travelers’ diarrhea with trimethoprim/sulfamethoxazole and with trimethoprim alone. <i>N Engl J Med</i>. 1982; 307:841-4. http://www.ncbi.nlm.nih.gov/pubmed/7050714?dopt=AbstractPlus</p><p>113. DuPont HL, Galindo E, Evans DG et al. Prevention of travelers’ diarrhea with trimethoprim-sulfamethoxazole and trimethoprim alone. <i>Gastroenterology</i>. 1983; 84:75-80. http://www.ncbi.nlm.nih.gov/pubmed/6336616?dopt=AbstractPlus</p><p>114. National Institutes of Health Office of Medical Applications of Research. Consensus conference: travelers’ diarrhea. <i>JAMA</i>. 1985; 253:2700-4. http://www.ncbi.nlm.nih.gov/pubmed/2985834?dopt=AbstractPlus</p><p>115. DuPont HL, Ericsson CD, Johnson PC. Chemotherapy and chemoprophylaxis of travelers’ diarrhea. <i>Ann Intern Med</i>. 1985; 102:260-1. http://www.ncbi.nlm.nih.gov/pubmed/3966763?dopt=AbstractPlus</p><p>116. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2002. <i>MMWR Morb Mortal Wkly Rep</i>. 2002; 51(No. RR-6):1-78. http://www.cdc.gov/mmwr/PDF/rr/rr5106.pdf</p><p>117. Wharton JM, Coleman DL, Wofsy CB et al. Trimethoprim-sulfamethoxazole or pentamidine for <i>Pneumocystis carinii</i> pneumonia in the acquired immunodeficiency syndrome: a prospective randomized trial. <i>Ann Intern Med</i>. 1986; 105:37-44. http://www.ncbi.nlm.nih.gov/pubmed/3521428?dopt=AbstractPlus</p><p>118. Lorber B. Listeriosis. <i>Clin Infect Dis</i>. 1997; 24:1-11. http://www.ncbi.nlm.nih.gov/pubmed/8994747?dopt=AbstractPlus</p><p>119. Anon. Drugs for parasitic infections. <i>Med Lett Drugs Ther</i>. Aug 2004. From the Medical Letter website (http://www.medletter.com).</p><p>120. DeHovitz JA, Pape JW, Boncy M et al. Clinical manifestations and therapy of <i>Isospora belli</i> infection in patients with the acquired immunodeficiency syndrome. <i>N Engl J Med</i>. 1986; 315:87-90. http://www.ncbi.nlm.nih.gov/pubmed/3487730?dopt=AbstractPlus</p><p>121. Anon. The choice of antibacterial drugs. <i>Med Lett Drugs Ther</i>. 2001; 43:69-78. http://www.ncbi.nlm.nih.gov/pubmed/11518876?dopt=AbstractPlus</p><p>122. DeRemee RA, McDonald TJ, Weiland LH. Wegener’s granulomatosis: observations on treatment with antimicrobial agents. <i>Mayo Clin Proc</i>. 1985; 60:27-32. http://www.ncbi.nlm.nih.gov/pubmed/3871238?dopt=AbstractPlus</p><p>123. West BC, Todd JR, King JW. Wegener granulomatosis and trimethoprim-sulfamethoxazole: complete remission after a twenty-year course. <i>Ann Intern Med</i>. 1987; 106:840-2. http://www.ncbi.nlm.nih.gov/pubmed/3495214?dopt=AbstractPlus</p><p>124. MacDonald KJS, Green CM, Kenicer KJA. Pustular dermatosis induced by co-trimoxazole. <i>BMJ</i>. 1986; 293:1279-80. http://www.ncbi.nlm.nih.gov/pubmed/3096466?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=1342113&amp;blobtype=pdf</p><p>125. Hughes WT, Rivera GK, Schell MJ et al. Successful intermittent chemoprophylaxis for <i>Pneumocystis carinii</i> pneumonitis. <i>N Engl J Med</i>. 1987; 316:1627-32. http://www.ncbi.nlm.nih.gov/pubmed/3495732?dopt=AbstractPlus</p><p>126. Marchant CD, Shurin PA, Johnson CE et al. A randomized controlled trial of amoxicillin plus clavulanate compared with cefaclor for treatment of acute otitis media. <i>J Pediatr</i>. 1986; 109:891-6. http://www.ncbi.nlm.nih.gov/pubmed/3534203?dopt=AbstractPlus</p><p>127. Van Hare GF, Shurin PA, Marchant CD et al. Acute otitis media caused by <i>Branhamella catarrhalis</i>: biology and therapy. <i>Rev Infect Dis</i>. 1987; 9:16-27. http://www.ncbi.nlm.nih.gov/pubmed/3493519?dopt=AbstractPlus</p><p>128. Odio CM, Kusmiesz H, Shelton S et al. Comparative treatment trial of Augmentin versus cefaclor for acute otitis media with effusion. <i>Pediatrics</i>. 1985; 75:819-26. http://www.ncbi.nlm.nih.gov/pubmed/4039433?dopt=AbstractPlus</p><p>129. Van Hare GF, Shurin PA. The increasing importance of <i>Branhamella catarrhalis</i> in respiratory infections. <i>Pediatr Infect Dis J</i>. 1987; 6:92-4. http://www.ncbi.nlm.nih.gov/pubmed/3547295?dopt=AbstractPlus</p><p>130. Bluestone CD. Otitis media and sinusitis in children: role of <i>Branhamella catarrhalis</i>. <i>Drugs</i>. 1986; 31(Suppl 3):132-41. http://www.ncbi.nlm.nih.gov/pubmed/3732081?dopt=AbstractPlus</p><p>131. Centers for Disease Control. Antibiotic-resistant strains of <i>Neisseria gonorrhoeae</i>: policy guidelines for detection, management, and control. <i>MMWR Morb Mortal Wkly Rep</i>. 1987; 36(Suppl 5S):1-18S. http://www.ncbi.nlm.nih.gov/pubmed/3099157?dopt=AbstractPlus</p><p>132. Food and Drug Administration. Sulfiting agents; labeling for human use; warning statements. [21 CFR Part 201] <i>Fed Regist</i>. 1986; 51:43900-5.</p><p>133. Axelson JA, Clark RH, Ancerewicz S. Wegener granulomatosis and trimethoprim-sulfamethoxazole. <i>Ann Intern Med</i>. 1987; 107:600. http://www.ncbi.nlm.nih.gov/pubmed/3498420?dopt=AbstractPlus</p><p>134. Food and Drug Administration. Serious adverse reactions with sulfonamides. <i>FDA Drug Bull</i>. 1984; 14:5-6. http://www.ncbi.nlm.nih.gov/pubmed/6734993?dopt=AbstractPlus</p><p>135. Glaxo Wellcome. Septra<sup></sup> I.V. infusion prescribing information. Research Triangle Park, NC; 1997 Apr.</p><p>136. Cohn DL, Penley KA, Judson RN et al. The acquired immunodeficiency syndrome and a trimethoprim-sulfamethoxazole adverse reaction. <i>Ann Intern Med</i>. 1984; 100:311.</p><p>137. Mitsuyasu R, Groopman J, Volberding P. Cutaneous reaction to trimethoprim-sulfamethoxazole in patients with AIDS and Kaposi’s sarcoma. <i>N Engl J Med</i>. 1983; 308:1535-6. http://www.ncbi.nlm.nih.gov/pubmed/6222258?dopt=AbstractPlus</p><p>138. Wofsy CB. Use of trimethoprim-sulfamethoxazole in the treatment of <i>Pneumocystis carinii</i> pneumonitis in patients with acquired immunodeficiency syndrome. <i>Rev Infect Dis</i>. 1987; 9(Suppl 2):S184-94. http://www.ncbi.nlm.nih.gov/pubmed/3554457?dopt=AbstractPlus</p><p>139. Smith RM, Iwamoto GK, Richerson HB et al. Trimethoprim-sulfamethoxazole desensitization in the acquired immunodeficiency syndrome. <i>Ann Intern Med</i>. 1987; 106:335-6. http://www.ncbi.nlm.nih.gov/pubmed/3492167?dopt=AbstractPlus</p><p>140. Hughes TE, Almgren JD, McGuffin RW et al. Co-trimoxazole desensitization in bone marrow transplantation. <i>Ann Intern Med</i>. 1986; 105:148. http://www.ncbi.nlm.nih.gov/pubmed/3521426?dopt=AbstractPlus</p><p>141. Gibbons RB, Lindauer JA. Successful treatment of <i>Pneumocystis carinii</i> pneumonia with trimethoprim-sulfamethoxazole in hypersensitive AIDS patients. <i>JAMA</i>. 1985; 253:1259-60. http://www.ncbi.nlm.nih.gov/pubmed/3871490?dopt=AbstractPlus</p><p>142. Colebunders R, Izaley L, Bila K et al. Cutaneous reactions to trimethoprim-sulfamethoxazole in African patients with acquired immunodeficiency syndrome. <i>Ann Intern Med</i>. 1987; 107:599-600. http://www.ncbi.nlm.nih.gov/pubmed/2957947?dopt=AbstractPlus</p><p>143. Hazel E, Sethi N, Jacquette G et al. Diminished sulfa-trimethoprim(ST) toxicity in Blacks treated for <i>Pneumocystis carinii</i> pneumonia (PCP). III International Conference on Acquired Immunodeficiency Syndrome (AIDS); 1987 June 1–5, Washington, DC. Washington, DC: US Department of Health and Human Services and the World Health Organization; 1987:F.3.2. Abstract.</p><p>144. DeHovitz JA, Johnson WD Jr, Pape JW. Cutaneous reactions to trimethoprim-sulfamethoxazole in Haitians. <i>Ann Intern Med</i>. 1985; 103:479-80. http://www.ncbi.nlm.nih.gov/pubmed/3161443?dopt=AbstractPlus</p><p>145. Doern GV, Jorgensen JH, Thornsberry C et al. National collaborative study of the prevalence of antimicrobial resistance among clinical isolates of <i>Haemophilus influenzae</i>. 1988; 32:180-5.</p><p>146. Israel HL. Sulfamethoxazole-trimethoprim therapy for Wegener’s granulomatosis. <i>Arch Intern Med</i>. 1988; 148:2293-5. http://www.ncbi.nlm.nih.gov/pubmed/3263099?dopt=AbstractPlus</p><p>147. Spiera H, Lawson W, Weinrauch H. Wegener’s granulomatosis treated with sulfamethoxazole- trimethoprim: report of a case. <i>Arch Intern Med</i>. 1988; 148:2065-6. http://www.ncbi.nlm.nih.gov/pubmed/3261974?dopt=AbstractPlus</p><p>148. Kaplan LD, Wofsy CB, Volberding PA. Treatment of patients with acquired immunodeficiency syndrome and associated manifestations. <i>JAMA</i>. 1987; 257:1367-74. http://www.ncbi.nlm.nih.gov/pubmed/3546745?dopt=AbstractPlus</p><p>149. Hughes WT. <i>Pneumocystis carinii</i> pneumonitis. <i>N Engl J Med</i>. 1987; 317:1021-3. http://www.ncbi.nlm.nih.gov/pubmed/2958709?dopt=AbstractPlus</p><p>150. Anon. Treatment of <i>Pneumocystis carinii</i> pneumonia. <i>Med Lett Drugs Ther</i>. 1987; 29:103-4. http://www.ncbi.nlm.nih.gov/pubmed/2959845?dopt=AbstractPlus</p><p>151. Kovacs JA, Masur H. <i>Pneumocystis carinii</i> pneumonia: therapy and prophylaxis. <i>J Infect Dis</i>. 1988; 158:254-9. http://www.ncbi.nlm.nih.gov/pubmed/2969023?dopt=AbstractPlus</p><p>152. Glatt AE, Chirgwin K, Landesman SH. Treatment of infections associated with human immunodeficiency virus. <i>N Engl J Med</i>. 1988; 318:1439-48. http://www.ncbi.nlm.nih.gov/pubmed/3285211?dopt=AbstractPlus</p><p>153. Rankin JA, Collman R, Daniele RP. Acquired immunodeficiency syndrome and the lung. <i>Chest</i>. 1988; 94:155-64. http://www.ncbi.nlm.nih.gov/pubmed/3289833?dopt=AbstractPlus</p><p>154. Sattler FR, Cowan R, Nielsen DM et al. Trimethoprim-sulfamethoxazole compared with pentamidine for treatment of <i>Pneumocystis carinii</i> pneumonia in the acquired immunodeficiency syndrome: a prospective, noncrossover study. <i>Ann Intern Med</i>. 1988; 109:280-7. http://www.ncbi.nlm.nih.gov/pubmed/3260759?dopt=AbstractPlus</p><p>155. Fischl MA, Dickinson GM, La Voie L. Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for <i>Pneumocystis carinii</i> pneumonia in AIDS. <i>JAMA</i>. 1988; 259:1185-9. http://www.ncbi.nlm.nih.gov/pubmed/3257532?dopt=AbstractPlus</p><p>156. Anon. Prevention of <i>Pneumocystis carinii</i> pneumonia. <i>Med Lett Drugs Ther</i>. 1988; 30:94-5. http://www.ncbi.nlm.nih.gov/pubmed/3050408?dopt=AbstractPlus</p><p>157. Kaplan LD, Abrams DI, Wofsy CB et al. Trimethoprim-sulfamethoxazole prophylaxis against <i>Pneumocystis carinii</i> pneumonia in acquired immunodeficiency syndrome (AIDS). <i>Clin Res</i>. 1986; 33:406A.</p><p>158. Borucki MJ, Matzke DS, Pollard RB. Tremor induced by trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome (AIDS). <i>Ann Intern Med</i>. 1988; 109:77-8. http://www.ncbi.nlm.nih.gov/pubmed/2967659?dopt=AbstractPlus</p><p>159. Centers for Disease Control and Prevention. Health information for international travel, 2003–2004. Atlanta, GA: US Department of Health and Human Services; 2003:13-39,99-116,227,231-5,249-50. Updates available from CDC website (http://www.cdc.gov/travel/yb/index.htm).</p><p>160. Arnold PA, Guglielmo BJ, Hollander H. Severe hypersensitivity reaction upon rechallenge with trimethoprim-sulfamethoxazole in a patient with AIDS. <i>Drug Intell Clin Pharm</i>. 1988; 22:43-5. http://www.ncbi.nlm.nih.gov/pubmed/2965002?dopt=AbstractPlus</p><p>161. Greenberger PA, Patterson R. Management of drug allergy in patients with acquired immunodeficiency syndrome. <i>J Allergy Clin Immunol</i>. 1987; 79:484-8. http://www.ncbi.nlm.nih.gov/pubmed/3819229?dopt=AbstractPlus</p><p>162. Papakonstantinou G, Fuessel H, Hehlmann R. Trimethoprim-sulfamethoxazole desensitization in AIDS. <i>Klin Wochenschr</i>. 1988; 66:351-3. http://www.ncbi.nlm.nih.gov/pubmed/3260637?dopt=AbstractPlus</p><p>163. Warren JW, Abrutyn E, Hebel JR et al. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. <i>Clin Infect Dis</i>. 1999; 29:745-58. http://www.ncbi.nlm.nih.gov/pubmed/10589881?dopt=AbstractPlus</p><p>164. US Public Health Service Immunization Practices Advisory Committee (ACIP). Diphtheria, tetanus, and pertussis: recommendations for vaccine use and other preventive measures. <i>MMWR Morb Mortal Wkly Rep</i>. 1991; 40(Suppl RR-10):1-28. http://www.ncbi.nlm.nih.gov/pubmed/1898620?dopt=AbstractPlus</p><p>165. Cullen AS, Cullen HB. Whooping-cough: prophylaxis with co-trimoxazole. <i>Lancet</i>. 1978; 1:556. http://www.ncbi.nlm.nih.gov/pubmed/76096?dopt=AbstractPlus</p><p>166. Arneil GC, McAllister TA. Whooping-cough in infants: antimicrobial prophylaxis? <i>Lancet</i>. 1977; 2:33-4. Letter. (IDIS 75690)</p><p>167. Rabo E. Drug prophylaxis in pertussis. <i>Lancet</i>. 1977; 2:707-8. http://www.ncbi.nlm.nih.gov/pubmed/71510?dopt=AbstractPlus</p><p>168. Arneil GC, McAllister TA. Drug prophylaxis in pertussis. <i>Lancet</i>. 1977; 2:708. http://www.ncbi.nlm.nih.gov/pubmed/71511?dopt=AbstractPlus</p><p>169. Adcock KJ, Reddy S, Okubadejo OA et al. Trimethoprim/sulphamethoxazole in pertussis: comparison with tetracycline. <i>Arch Dis Child</i>. 1972; 47:311-3. http://www.ncbi.nlm.nih.gov/pubmed/4336846?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=1648034&amp;blobtype=pdf</p><p>170. Fishman JA. Treatment of infection due to Pneumocystis carinii. <i>Antimicrob Agents Chemother</i>. 1998; 42:1309-14. http://www.ncbi.nlm.nih.gov/pubmed/9624465?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=105593&amp;blobtype=pdf</p><p>171. Pierone G, Masci JR, Nicholas P. Pentamidine and hypoglycaemia. <i>Lancet</i>. 1989; 2:864. http://www.ncbi.nlm.nih.gov/pubmed/2571784?dopt=AbstractPlus</p><p>172. US Public Health Service Task Force on Antipneumocystis Prophylaxis for Patients with Human Immunodeficiency Virus Infection. Recommendations for prophylaxis against <i>Pneumocystis carinii</i> pneumonia for adults and adolescents infected with human immunodeficiency virus. <i>MMWR Morb Mortal Wkly Rep</i>. 1992; 41(No. RR-4):1-11.</p><p>173. Masur H, Lane HC, Kovacs JA et al. Pneumocystis pneumonia: from bench to clinic. <i>Ann Intern Med</i>. 1989; 111:813-26. http://www.ncbi.nlm.nih.gov/pubmed/2683916?dopt=AbstractPlus</p><p>174. American Academy of Pediatrics Committee on Fetus and Newborn and Committee on Drugs. Benzyl alcohol: toxic agent in neonatal units. <i>Pediatrics</i>. 1983; 72:356-8. http://www.ncbi.nlm.nih.gov/pubmed/6889041?dopt=AbstractPlus</p><p>175. Anon. Benzyl alcohol may be toxic to newborns. <i>FDA Drug Bull</i>. 1982; 12:10-1. http://www.ncbi.nlm.nih.gov/pubmed/7188569?dopt=AbstractPlus</p><p>176. Anon. Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982; 31:290-1. http://www.ncbi.nlm.nih.gov/pubmed/6810084?dopt=AbstractPlus</p><p>177. Gershanik J, Boecler B, Ensley H et al. The gasping syndrome and benzyl alcohol poisoning. <i>N Engl J Med</i>. 1982; 307:1384-8. http://www.ncbi.nlm.nih.gov/pubmed/7133084?dopt=AbstractPlus</p><p>178. Menon PA, Thach BT, Smith CH et al. Benzyl alcohol toxicity in a neonatal intensive care unit: incidence, symptomatology, and mortality. <i>Am J Perinatol</i>. 1984; 1:288-92. http://www.ncbi.nlm.nih.gov/pubmed/6440575?dopt=AbstractPlus</p><p>179. Bharija SC, Singh M, Belhaj MS. Fixed drug eruption in an 8-month-old infant. <i>Dermatologica</i>. 1988; 176:108. http://www.ncbi.nlm.nih.gov/pubmed/2967210?dopt=AbstractPlus</p><p>180. Anon. Advice for travelers. <i>Med Lett Treat Guid</i>. 2004; 2:33-40.</p><p>181. Ericsson CD, DuPont HL, Mathewson JJ et al. Treatment of traveler’s diarrhea with sulfamethoxazole and trimethoprim and loperamide. <i>JAMA</i>. 1990; 263:257-61. http://www.ncbi.nlm.nih.gov/pubmed/2403603?dopt=AbstractPlus</p><p>182. Ericsson CD, Johnson PC, DuPont HL et al. Ciprofloxacin or trimethoprim-sulfamethoxazole as initial therapy for travelers’ diarrhea. <i>Ann Intern Med</i>. 1987; 106:216-20. http://www.ncbi.nlm.nih.gov/pubmed/3541724?dopt=AbstractPlus</p><p>183. DuPont HL, Ericsson CD, Reves RR et al. Antimicrobial therapy for travelers’ diarrhea. <i>Rev Infect Dis</i>. 1986; 8(Suppl 2):S217-22. http://www.ncbi.nlm.nih.gov/pubmed/3523718?dopt=AbstractPlus</p><p>184. DuPont HL, Ericsson CD, Galindo E et al. Antimicrobial therapy of traveler’s diarrhea. <i>Scand J Gastroenterol</i>. 1983; 18(Suppl 84):99-105.</p><p>185. Ericsson CD, Johnson PC, DuPont HL et al. Role of a novel antidiarrheal agent, BW942C, alone or in combination with trimethoprim-sulfamethoxazole in the treatment of travelers’ diarrhea. <i>Antimicrob Agents Chemother</i>. 1986; 29:1040-6. http://www.ncbi.nlm.nih.gov/pubmed/3524436?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=180497&amp;blobtype=pdf</p><p>186. Roche. Bactrim<sup></sup> (trimethoprim and sulfamethoxazole) tablets, double-strength tablets, pediatric suspension prescribing information. Nutley, NJ; 1998 Aug.</p><p>187. Johnson PC, Ericsson CD, DuPont HL et al. Comparison of loperamide with bismuth subsalicylate for the treatment of acute travelers’ diarrhea. <i>JAMA</i>. 1986; 255:757-60. http://www.ncbi.nlm.nih.gov/pubmed/3944976?dopt=AbstractPlus</p><p>188. Wiström J, Jertborn M, Hedström SA et al. Short-term self-treatment of travellers’ diarrhoea with norfloxacin; a placebo-controlled study. <i>J Antimicrob Chemother</i>. 1989; 23:905-13. http://www.ncbi.nlm.nih.gov/pubmed/2668252?dopt=AbstractPlus</p><p>189. Anon. Quinolones in acute non-travelers’ diarrhoea. <i>Lancet</i>. 1990; 336:282.</p><p>190. Steffen R. Worldwide efficacy of bismuth subsalicylate in the treatment of travelers’ diarrhea. <i>Clin Infect Dis</i>. 1990; 12(Suppl 1):S80-6.</p><p>191. Ericsson CD, DuPont HL, Johnson PC. Nonantibiotic therapy for travelers’ diarrhea. <i>Rev Infect Dis</i>. 1986; 8(Suppl 2):S202-6.</p><p>192. Sack RB, Froehlich JL, Orskov F et al. Doxycycline is an effective treatment for travellers’ diarrhoea. <i>J Diarrhoeal Dis Res</i>. 1986; 4:144-8. http://www.ncbi.nlm.nih.gov/pubmed/3584904?dopt=AbstractPlus</p><p>193. Pavia AT, Tauxe RU. Travel to the Soviet Union: is diarrhea a risk? <i>JAMA</i>. 1987; 258:1661.</p><p>194. Young FE, Nightingale SL. FDA’s newly designated treatment INDs. <i>JAMA</i>. 1988; 260:224-5. http://www.ncbi.nlm.nih.gov/pubmed/2838651?dopt=AbstractPlus</p><p>195. Nightingale SL. From the Food and Drug Administration. <i>JAMA</i>. 1988; 259:2064.</p><p>196. Anon. Treatment IND for AIDS drug. <i>FDA Drug Bull</i>. 1988; 18:2.</p><p>197. Allegra CJ, Chabner BA, Tuazon CU et al. Trimetrexate for the treatment of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. <i>N Engl J Med</i>. 1987; 317:978-85. http://www.ncbi.nlm.nih.gov/pubmed/2958710?dopt=AbstractPlus</p><p>198. AIDS Program, Treatment Branch, National Institute of Allergy and Infectious Diseases and Warner-Lambert Company. A treatment protocol for the use of trimetrexate with leucovorin rescue for AIDS patients with Pneumocystis carinii pneumonia and serious intolerance to approved therapies. No. TX 301. Bethesda, MD; 1988 Jun 7.</p><p>199. Schneider MME, Borleffs JCC, Stolk RP et al. Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1 infected patients treated with highly active antiretroviral therapy. <i>Lancet</i>. 1999; 353:201-3. http://www.ncbi.nlm.nih.gov/pubmed/9923876?dopt=AbstractPlus</p><p>200. Doepel LK. HHS news regarding an inexpensive drug (co-trimoxazole) used to treat <i>Pneumocystis carinii</i> pneumonia (PCP) has been found to be superior to the only drug (pentamidine) currently approved for PCP prophylaxis in preventing a second episode of PCP. US Department of Health and Human Services Public Health Service. 1991 Sep 6.</p><p>201. National Institute of Allergy and Infectious Diseases backgrounder: questions and answers about ACTG protocol 021 and PCP prevention. Bethesda, MD: National Institutes of Health Office of Communications; 1991 Sep 6.</p><p>202. Working Group on PCP Prophylaxis in children. Guidelines for prophylaxis against <i>Pneumocystis carinii</i> pneumonia for children infected with human immunodeficiency virus. <i>MMWR Morb Mortal Wkly Rep</i>. 1991; 40(Suppl RR-2):1-13. http://www.ncbi.nlm.nih.gov/pubmed/1898620?dopt=AbstractPlus</p><p>203. Anon. Guidelines established for PCP prophylaxis in infants and children infected with HIV. <i>NIAID AIDS Agenda</i>. 1991; (Mar/Apr):6.</p><p>204. Castellano AR, Nettleman MD. Cost and benefit of secondary prophylaxis for <i>Pneumocystis carinii</i> pneumonia. <i>JAMA</i>. 1991; 266:820-4. http://www.ncbi.nlm.nih.gov/pubmed/1907671?dopt=AbstractPlus</p><p>205. McSherry G, Wright M, Oleska J et al. Frequency of serious adverse reactions (SAR) to trimethoprim-sulfamethoxazole (TMP-SMZ) and pentamidine (P) among children with human immunodeficiency virus 1 (HIV-1) infection. Proceedings of ICAAC Los Angeles 1988. Abstract No. 1357.</p><p>206. Connor E, Bagarazzi M, McSherry G et al. Clinical and laboratory correlates on <i>Pneumocystis carinii</i> pneumonia in children infected with HIV. <i>JAMA</i>. 1991; 265:1693-7. http://www.ncbi.nlm.nih.gov/pubmed/1672168?dopt=AbstractPlus</p><p>207. Valeriano-Marcet J, Spiera H. Treatment of Wegener’s granulomatosis with sulfamethoxazole-trimethoprim. <i>Arch Intern Med</i>. 1991; 151:1649-52. http://www.ncbi.nlm.nih.gov/pubmed/1872670?dopt=AbstractPlus</p><p>208. Kovacs A, Frederick T, Church J et al. CD4 T-lymphocyte counts and <i>Pneumocystis carinii</i> pneumonia in pediatric HIV infection. <i>JAMA</i>. 1991; 265:1698-1703. http://www.ncbi.nlm.nih.gov/pubmed/1672169?dopt=AbstractPlus</p><p>209. Ruskin J, La Riviere M. Low-dose co-trimoxazole for prevention of <i>Pneumocystis carinii</i> pneumonia in human immunodeficiency virus disease. <i>Lancet</i>. 1991; 337:468-71. http://www.ncbi.nlm.nih.gov/pubmed/1671479?dopt=AbstractPlus</p><p>210. Freedberg KA, Tosteson ANA, Cohen CJ et al. Inhaled pentamidine and prevention of pneumocystis pneumonia. <i>N Engl J Med</i>. 1991; 325:735. http://www.ncbi.nlm.nih.gov/pubmed/1908059?dopt=AbstractPlus</p><p>211. Bender BS. Inhaled pentamidine and prevention of pneumocystis pneumonia. <i>N Engl J Med</i>. 1991; 325:736.</p><p>212. Falloon J, Masur H. The era of aerosol pentamidine prophylaxis: the beginning or the end? <i>Am J Med</i>. 1991; 90:415-7. Editorial.</p><p>213. Fitzpatrick JE, Tyler H, Gramstad ND. Treatment of chancroid: comparison of sulfamethoxazole-trimethoprim with recommended therapies. <i>JAMA</i>. 1981; 246:1804-5. http://www.ncbi.nlm.nih.gov/pubmed/7024580?dopt=AbstractPlus</p><p>214. Naamara W, Plummer FA, Greenblatt RM et al. Treatment of chancroid with ciprofloxacin. A prospective, randomized clinical trial. <i>Am J Med</i>. 1987; 82(Suppl 4A):317-20. http://www.ncbi.nlm.nih.gov/pubmed/3555055?dopt=AbstractPlus</p><p>215. Schmid GP. The treatment of chancroid. <i>JAMA</i>. 1986; 255:1757-62. http://www.ncbi.nlm.nih.gov/pubmed/3512872?dopt=AbstractPlus</p><p>216. Fransen L, Nsanze H, Jo-Ndinya-Achola et al. A comparison of single-dose spectinomycin with five days of trimethoprim-sulfamethoxazole for the treatment of chancroid. <i>Sex Transm Dis</i>. 1987; 14:98-101. http://www.ncbi.nlm.nih.gov/pubmed/2956702?dopt=AbstractPlus</p><p>217. van der Ven AJAM, Koopmans PP, Vree TB et al. Adverse reactions to co-trimoxazole in HIV infection. <i>Lancet</i>. 1991; 338:431-3. http://www.ncbi.nlm.nih.gov/pubmed/1678095?dopt=AbstractPlus</p><p>218. Wormser GP, Horowitz HW, Duncanson FP et al. Low-dose intermittent trimethoprim-sulfamethoxazole for prevention of <i>Pneumocystis carinii</i> pneumonia in patients with human immunodeficiency virus infection. <i>Arch Intern Med</i>. 1991; 151:688-92. http://www.ncbi.nlm.nih.gov/pubmed/1901482?dopt=AbstractPlus</p><p>219. Reviewers’ comments (personal observations).</p><p>220. National Institute of Allergy and Infectious Diseases Division of AIDS. Note to physicians: important therapeutic information on prevention of recurrent <i>Pneumocystis carinii</i> pneumonia in persons with AIDS. Bethesda, MD: National Institutes of Health; 1991 Oct 11.</p><p>221. Allen UD, Read SE. <i>Pneumocystis carinii</i> pneumonia [PCP] prophylaxis for HIV-infected infants: a decision analysis. Proceedings of ICAAC Chicago 1991. Abstract No. 627.</p><p>222. Bass JW. Erythromycin for pertussis: probable reason for past failures. <i>Lancet</i>. 1985; 2:147. http://www.ncbi.nlm.nih.gov/pubmed/2862331?dopt=AbstractPlus</p><p>223. Bass JW. Erythromycin for treatment and prevention of pertussis. <i>Pediatr Infect Dis</i>. 1986; 5:154-7. http://www.ncbi.nlm.nih.gov/pubmed/2868449?dopt=AbstractPlus</p><p>224. Steketee RW, Wassilak SGF, Adkins WN et al. Evidence for a high attack rate and efficacy of erythromycin prophylaxis in a pertussis outbreak in a facility for the developmentally disabled. <i>J Infect Dis</i>. 1988; 157:434-40. http://www.ncbi.nlm.nih.gov/pubmed/3257783?dopt=AbstractPlus</p><p>225. Halsey NA, Welling MA, Lehman RM. Nosocomial pertussis: a failure of erythromycin treatment and prophylaxis. <i>Am J Dis Child</i>. 1980; 134:421-2.</p><p>226. Bass JW. Use of erythromycin in pertussis outbreaks. <i>Pediatrics</i>. 1983; 72:748-9. http://www.ncbi.nlm.nih.gov/pubmed/6356008?dopt=AbstractPlus</p><p>227. Anon. Recommendations for prophylaxis against <i>Pneumocystis carinii</i> pneumonia for adults and adolescents infected with HIV. <i>JAMA</i>. 1992; 267:2294-9. http://www.ncbi.nlm.nih.gov/pubmed/1348788?dopt=AbstractPlus</p><p>228. Kovacs JA, Masur H. Prophylaxis for <i>Pneumocystis carinii</i> pneumonia in patients infected with human immunodeficiency virus. <i>Clin Infect Dis</i>. 1992; 14:1005-9. http://www.ncbi.nlm.nih.gov/pubmed/1350925?dopt=AbstractPlus</p><p>229. Carr A, Tindall B, Brew BJ et al. Low-dose trimethoprim-sulfamethoxazole prophylaxis for toxoplasmic encephalitis in patients with AIDS. <i>Ann Intern Med</i>. 1992; 117:106-11. http://www.ncbi.nlm.nih.gov/pubmed/1351371?dopt=AbstractPlus</p><p>230. Beaman MH, Luft BJ, Remington JS. Prophylaxis for toxoplasmosis in AIDS. <i>Ann Intern Med</i>. 1992; 117:163-4. http://www.ncbi.nlm.nih.gov/pubmed/1605431?dopt=AbstractPlus</p><p>231. Swerdlow DL, Ries AA. Cholera in the Americas: guidelines for the clinician. <i>JAMA</i>. 1992; 267:1495-9. http://www.ncbi.nlm.nih.gov/pubmed/1371570?dopt=AbstractPlus</p><p>232. Scheld WM. Evaluation of rifampin and other antibiotics against <i>Listeria monocytogenes</i> in vitro and in vivo. <i>Rev Infect Dis</i>. 1983; 5(Suppl 3):S593-9.</p><p>233. Levitz RE, Quintiliani R. Trimethoprim-sulfamethoxazole for bacterial meningitis. <i>Ann Intern Med</i>. 1984; 100:881-90. http://www.ncbi.nlm.nih.gov/pubmed/6372565?dopt=AbstractPlus</p><p>234. Berenguer J, Solera J, Diaz MD et al. Listeriosis in patients infected with human immunodeficiency virus. <i>Rev Infect Dis</i>. 1991; 13:115-9. http://www.ncbi.nlm.nih.gov/pubmed/2017609?dopt=AbstractPlus</p><p>235. Friedrich LV, White RL, Reboli AC. Pharmacodynamics of trimethoprim-sulfamethoxazole in <i>Listeria</i> meningitis: a case report. <i>Pharmacotherapy</i>. 1990; 10:301-4. http://www.ncbi.nlm.nih.gov/pubmed/2117750?dopt=AbstractPlus</p><p>236. Overturf GD. Use of trimethoprim-sulfamethoxazole in pediatric infections: relative merits of intravenous administration. <i>Rev Infect Dis</i>. 1987; 9(Suppl 2):S168-76.</p><p>237. Günther G, Philipson A. Oral trimethoprim as follow-up treatment of meningitis caused by <i>Listeria monocytogenes</i>. <i>Rev Infect Dis</i>. 1988; 10:53-5. http://www.ncbi.nlm.nih.gov/pubmed/3258438?dopt=AbstractPlus</p><p>238. Hardy WD, Feinberg J, Finkelstein DM et al. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of <i>Pneumocystis carinii</i> pneumonia in patients with the acquired immunodeficiency syndrome: AIDS Clinical Trials Group Protocol 021. <i>N Engl J Med</i>. 1992; 327:1842-8. http://www.ncbi.nlm.nih.gov/pubmed/1448121?dopt=AbstractPlus</p><p>239. US Public Health Service Task Force on Antipneumocystis Prophylaxis in Patients with Human Immunodeficiency Virus Infection. Recommendations for prophylaxis against <i>Pneumocystis carinii</i> pneumonia for persons infected with human immunodeficiency virus. <i>J Acquir Immune Defic Syndr</i>. 1993; 6:46-55. http://www.ncbi.nlm.nih.gov/pubmed/8417174?dopt=AbstractPlus</p><p>240. Schneider MME, Hoepelman AIM, Eeftinck Schattenkerk JKM et al. A controlled trial of aerosolized pentamidine or trimethoprim–sulfamethoxazole as primary prophylaxis against <i>Pneumocystis carinii</i> pneumonia in patients with human immunodeficiency virus infection. <i>N Engl J Med</i>. 1992; 327:1836-41. http://www.ncbi.nlm.nih.gov/pubmed/1360145?dopt=AbstractPlus</p><p>241. Masur H. Prevention and treatment of pneumocystis pneumonia. <i>N Engl J Med</i>. 1992; 327:1853-60. http://www.ncbi.nlm.nih.gov/pubmed/1448123?dopt=AbstractPlus</p><p>242. Caeiro JP, Du-Pont HL. Management of travellers’ diarrhoea. <i>Drugs</i>. 1998; 56:73-81. http://www.ncbi.nlm.nih.gov/pubmed/9664200?dopt=AbstractPlus</p><p>243. Blum RN, Miller LA, Gaggini LC et al. Comparative trial of dapsone versus trimethoprim/sulfamethoxazole for primary prophylaxis of <i>Pneumocystis carinii</i> pneumonia. <i>J Acquir Immune Defic Syndr</i>. 1992; 5:341-7. http://www.ncbi.nlm.nih.gov/pubmed/1548570?dopt=AbstractPlus</p><p>244. Coker RJ, Nieman R, McBride M et al. Co-trimoxazole versus dapsone-pyrimethamine for prevention of <i>Pneumocystis carinii</i> pneumonia. <i>Lancet</i>. 1992; 340:1099. http://www.ncbi.nlm.nih.gov/pubmed/1357487?dopt=AbstractPlus</p><p>245. Stein DS, Stevens RC, Terry D et al. Use of low-dose trimethoprim-sulfamethoxazole thrice weekly for primary and secondary prophylaxis of <i>Pneumocystis carinii</i> pneumonia in human immunodeficiency virus-infected patients. <i>Antimicrob Agents Chemother</i>. 1991; 35:1705-9. http://www.ncbi.nlm.nih.gov/pubmed/1952835?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=245254&amp;blobtype=pdf</p><p>246. Martin MA, Cox PH, Beck K et al. A comparison of the effectiveness of three regimens in the prevention of <i>Pneumocystis carinii</i> pneumonia in human immunodeficiency virus–infected patients. <i>Arch Intern Med</i>. 1992; 152:523-8. http://www.ncbi.nlm.nih.gov/pubmed/1546914?dopt=AbstractPlus</p><p>247. Marinas JS, Stanford JF. A severe hypersensitive reaction to trimethoprim-sulfamethoxazole in a patient infected with human immunodeficiency virus. <i>Clin Infect Dis</i>. 1993; 16:178-9. http://www.ncbi.nlm.nih.gov/pubmed/8448304?dopt=AbstractPlus</p><p>248. Kelly JW, Dooley DP, Lattuada CP et al. A severe, unusual reaction to trimethoprim-sulfamethoxazole in patients infected with human immunodeficiency virus. <i>Clin Infect Dis</i>. 1992; 14:1034-9. http://www.ncbi.nlm.nih.gov/pubmed/1600003?dopt=AbstractPlus</p><p>249. Jost R, Stey C, Salomon F. Fatal drug-induced pancreatitis in HIV. <i>Lancet</i>. 1993; 341:1412. http://www.ncbi.nlm.nih.gov/pubmed/7684478?dopt=AbstractPlus</p><p>250. Harb GE, Jacobson MA. Human immunodeficiency virus (HIV) infection: does it increase susceptibility to adverse drug reactions? <i>Drug Safety</i>. 1993; 9:1-8.</p><p>251. Martin GJ, Paparello SF, Decker CF. A severe systemic reaction to trimethoprim-sulfamethoxazole in a patient infected with the human immunodeficiency virus. <i>Clin Infect Dis</i>. 1993; 16:175-6. http://www.ncbi.nlm.nih.gov/pubmed/8448303?dopt=AbstractPlus</p><p>252. Coopman SA, Johnson RA, Platt R et al. Cutaneous disease and drug reactions in HIV infection. <i>N Engl J Med</i>. 1993; 328:1670-4. http://www.ncbi.nlm.nih.gov/pubmed/8487826?dopt=AbstractPlus</p><p>253. Lee BL, Safrin S. Interactions and toxicities of drugs used in patients with AIDS. <i>Clin Infect Dis</i>. 1992; 14:773-9. http://www.ncbi.nlm.nih.gov/pubmed/1314104?dopt=AbstractPlus</p><p>254. Pozniak A, Weinberg J, Macleod G. HIV and co-trimoxazole toxicity. <i>Lancet</i>. 1991; 338:760-1. http://www.ncbi.nlm.nih.gov/pubmed/1679894?dopt=AbstractPlus</p><p>255. Centers for Disease Control and Prevention. Pertussis outbreaks—Massachusetts and Maryland, 1992. <i>MMWR Morb Mortal Wkly Rep</i>. 1993; 42:197-200. http://www.ncbi.nlm.nih.gov/pubmed/8446095?dopt=AbstractPlus</p><p>256. DuPont HL, Ericsson CD. Prevention and treatment of traveler’s diarrhea. <i>N Engl J Med</i>. 1993; 328:1821-7. http://www.ncbi.nlm.nih.gov/pubmed/8502272?dopt=AbstractPlus</p><p>257. Ericsson CD, DuPont HL. Travelers’ diarrhea: approaches to prevention and treatment. <i>Clin Infect Dis</i>. 1993; 16:616-26. http://www.ncbi.nlm.nih.gov/pubmed/8507751?dopt=AbstractPlus</p><p>258. National Institute of Allergy and Infectious Diseases, Bethesda, MD: Personal communication.</p><p>259. DuPont HL. Travellers’ diarrhoea: which antimicrobial? <i>Drugs</i>. 1993; 45:910-7.</p><p>260. U.S. Bioscience, Inc. Neutrexin<sup></sup> (trimetrexate glucuronate) for injection prescribing information. In: Barnhart ER, publisher. Physicians’ desk reference. 48th ed. Oradell, NJ: Medical Economics Company Inc; 1994(Suppl A):A44-7.</p><p>261. May T, Beuscart C, Reynes J et al. Trimethoprim-sulfamethoxazole versus aerosolized pentamidine for primary prophylaxis of <i>Pneumocystis carinii</i> pneumonia: a prospective, randomized, controlled clinical trial. <i>J Acquir Immune Defic Syndr</i>. 1994; 7:457-62. http://www.ncbi.nlm.nih.gov/pubmed/8158539?dopt=AbstractPlus</p><p>262. Gallant JE, Moore RD, Chaisson RE. Prophylaxis for opportunistic infections in patients with HIV infection. <i>Ann Intern Med</i>. 1994; 120:932-44. http://www.ncbi.nlm.nih.gov/pubmed/8172439?dopt=AbstractPlus</p><p>263. Smith GH. Treatment of infections in the patient with acquired immunodeficiency syndrome. <i>Arch Intern Med</i>. 1994; 154:959-73.</p><p>264. Rowe JM, Ciobanu N, Ascensao J et al. Recommended guidelines for the management of autologous and allogeneic bone marrow transplantation: a report from the Eastern Cooperative Oncology Group (ECOG). <i>Ann Intern Med</i>. 1994; 120:143-58. http://www.ncbi.nlm.nih.gov/pubmed/8256974?dopt=AbstractPlus</p><p>265. Osmond D, Charlebois E, Lang W et al. Changes in AIDS survival time in two San Francisco cohorts of homosexual men, 1983 to 1993. <i>JAMA</i>. 1994; 271:1083-7. http://www.ncbi.nlm.nih.gov/pubmed/7908703?dopt=AbstractPlus</p><p>266. Rigaud M, Pollack H, Leibovitz E et al. Efficacy of primary chemoprophylaxis against <i>Pneumocystis carinii</i> pneumonia during the first year of life in infants infected with human immunodeficiency virus type 1. <i>J Pediatr</i>. 1994; 125:476-80. http://www.ncbi.nlm.nih.gov/pubmed/7915306?dopt=AbstractPlus</p><p>267. National Institutes of Health Combined Clinical Staff Conference. Consensus conference: recent advances in the management of AIDS-related opportunistic infections. <i>Ann Intern Med</i>. 1994; 120:945-55. http://www.ncbi.nlm.nih.gov/pubmed/7909657?dopt=AbstractPlus</p><p>268. Kovacs JA, Kovacs AAS. PCP prophylaxis in paediatric HIV infection: time for a change? <i>Lancet</i>. 1994; 344:5-6. Letter.</p><p>269. Hoover DR, Saah AJ, Bacellar H et al. Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. <i>N Engl J Med</i>. 1992; 329:1992-6.</p><p>270. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing: eleventh informational supplement. NCCLS document M100-S12. NCCLS: Wayne, PA; 2002 Jan.</p><p>272. Anon. Drugs for treatment of acute otitis media in children. <i>Med Lett Drugs Ther</i>. 1994; 36:19-21. http://www.ncbi.nlm.nih.gov/pubmed/8107649?dopt=AbstractPlus</p><p>273. Pichichero ME. Assessing the treatment alternatives for acute otitis media. <i>Pediatr Infect Dis J</i>. 1994; 13:S27-34. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=2993315&amp;blobtype=pdf</p><p>274. Klein JO. Microbiologic efficacy of antibacterial drugs for acute otitis media. <i>Pediatr Infect Dis J</i>. 1993; 12:973-5. http://www.ncbi.nlm.nih.gov/pubmed/8108222?dopt=AbstractPlus</p><p>275. Bluestone CD, Stephenson JS, Martin LM. Ten-year review of otitis media pathogens. <i>Pediatr Infect Dis J</i>. 1992; 11:S7-11. http://www.ncbi.nlm.nih.gov/pubmed/1513611?dopt=AbstractPlus</p><p>276. Rosenfeld RM, Vertrees JE, Carr J et al. Clinical efficacy of antimicrobial drugs for acute otitis media: metaanalysis of 5400 children from thirty-three randomized trials. <i>J Pediatr</i>. 1994; 124:355-67. http://www.ncbi.nlm.nih.gov/pubmed/8120703?dopt=AbstractPlus</p><p>277. Del Beccaro MA, Mendelman PM, Inglis AF et al. Bacteriology of acute otitis media: a new perspective. <i>J Pediatr</i>. 1992; 120:81-4. http://www.ncbi.nlm.nih.gov/pubmed/1731029?dopt=AbstractPlus</p><p>278. Giebink GS, Canafax DM, Kempthorne J. Antimicrobial treatment of acute otitis media. <i>J Pediatr</i>. 1991; 119:495-500. http://www.ncbi.nlm.nih.gov/pubmed/1880671?dopt=AbstractPlus</p><p>280. US Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA) Prevention of Opportunistic Infections Working Group. 2001 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons with human immunodeficiency virus. From the US Department of Health and Human Services HIV/AIDS Information Services (AIDSinfo) website (http://aidsinfo.nih.gov).</p><p>281. Furrer H, Egger M, Opravil M et al. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1 infected adults treated with combination antiretroviral therapy. <i>N Engl J Med</i>. 1999; 340:1301-6. http://www.ncbi.nlm.nih.gov/pubmed/10219064?dopt=AbstractPlus</p><p>282. Centers for Disease Control and Prevention. 1995 revised guidelines for prophylaxis against <i>Pneumocystis carinii</i> pneumonia for children infected with or perinatally exposed to human immunodeficiency virus. <i>MMWR Morb Mortal Wkly Rep</i>. 1995; 44(No. RR-4):1-11. http://www.ncbi.nlm.nih.gov/pubmed/7799912?dopt=AbstractPlus http://www.cdc.gov/mmwr/PDF/rr/rr4404.pdf</p><p>283. Centers for Disease Control and Prevention. Prevention of plague: recommendations of the Advisory Committee on Immunization Practices (ACIP). <i>MMWR</i> 1996;45(No. RR-14):1-15.</p><p>284. Butler T. Yersinia species (including plague). In: Mandell GL, Bennett JE, Dolan R, eds. Principles and practices of infectious diseases. 4th ed. New York: Churchill Livingstone; 1995:2070-76.</p><p>285. Centers for Disease Control and Prevention. Human plague—India, 1994. <i>MMWR Morb Mortal Wkly Rep</i>. 1994; 43:689-91. http://www.ncbi.nlm.nih.gov/pubmed/8084331?dopt=AbstractPlus</p><p>286. Committee on Infectious Diseases, American Academy of Pediatrics. Red book: 2003 report of the Committee on Infectious Diseases. 26th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2003.</p><p>287. Weverling GS, Mocroft A, Ledergerber B et al. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection, Euro SIDA study group. <i>Lancet</i>. 1999; 353:1293-8. http://www.ncbi.nlm.nih.gov/pubmed/10218526?dopt=AbstractPlus</p><p>288. Centers for Disease Control and Prevention. Outbreak of cyclosporiasis—Northern Virginia–Washington, DC.–Baltimore, Maryland, metropolitan area, 1997. <i>MMWR Morb Mortal Wkly Rep</i>. 1997; 46:689-91. http://www.ncbi.nlm.nih.gov/pubmed/9256053?dopt=AbstractPlus</p><p>289. Helweg-Larsen J, Benfield TL, Eugen-Olsen J et al. Effects of mutations of Pneumocystis carinii dihydropteroate synthase gene on outcome of AIDS-associated P. carinii pneumonia. <i>Lancet</i>. 1998; 354:1347-51.</p><p>290. Meshnick S. Drug-resistant Pneumocystis carinii. <i>Lancet</i>. 1999; 354:1318-19. http://www.ncbi.nlm.nih.gov/pubmed/10533856?dopt=AbstractPlus</p><p>291. Klein JO. Selection of oral antimicrobial agents for otitis media and pharyngitis. <i>Infect Dis Clin Pract</i>. 1995; 4(Suppl 2):S88-94.</p><p>292. Pichichero ME, Cohen R. Shortened course of antibiotic therapy for acute otitis media, sinusitis and tonsillopharyngitis. <i>Pediatr Infect Dis J</i>. 1997; 16:680-95. http://www.ncbi.nlm.nih.gov/pubmed/9239773?dopt=AbstractPlus</p><p>293. McCracken GH. Treatment of acute otitis media in an era of increasing microbial resistance. <i>Pediatr Infect Dis J</i>. 1998; 17:576-9. http://www.ncbi.nlm.nih.gov/pubmed/9655564?dopt=AbstractPlus</p><p>294. Klein JO. Otitis media. <i>Clin Infect Dis J</i>. 1994; 19:823-33.</p><p>295. Klein JO. Clinical implications of antibiotic resistance for management of acute otitis media. <i>Pediatr Infect Dis J</i>. 1998; 17:1084-9. http://www.ncbi.nlm.nih.gov/pubmed/9850003?dopt=AbstractPlus</p><p>296. Gooch WM, Philips A, Rhoades R et al. Comparison of the efficacy, safety and acceptability of cefixime and amoxicillin/clavulanate in acute otitis media. <i>Pediatr Infect Dis J</i>. 1997; 16(Suppl):21-4.</p><p>297. Kafetzis DA. Multi-investigator evaluation of the efficacy and safety of cefprozil, amoxicillin-clavulanate, cefixime and cefaclor in the treatment of acute otitis media. <i>Eur J Clin Microbiol Infect Dis</i>. 1994; 13:857-65. http://www.ncbi.nlm.nih.gov/pubmed/7889960?dopt=AbstractPlus</p><p>298. Adler M, McDonald PJ, Trostmann U et al. Cefdinir versus amoxicillin/clavulanic acid in the treatment of suppurative acute otitis media in children. <i>Eur J Clin Microbiol Dis</i>. 1997; 16:214-9.</p><p>299. Gooch WM, Adelglass J, Kelsey DK et al. Loracarbef versus clarithromycin in children with acute otitis media with effusion. <i>Clin Ther</i>. 1999; 21:711-21. http://www.ncbi.nlm.nih.gov/pubmed/10363736?dopt=AbstractPlus</p><p>300. Hoppe HL, Johnson CE. Otitis media: focus on antimicrobial resistance and new treatment options. <i>Am J Health-Syst Pharm</i>. 198; 55:1881-97.</p><p>301. Bluestone CD. Ear and mastoid infections. In: Gorbach SL, Bartlett JG, Blacklow NR, eds. Infectious diseases. Philadelphia, PA: WB Saunders; 1998:530-9.</p><p>302. Dowell SF, Butler JC, Giebink GS et al. Acute otitis media: management and surveillance in an era of pneumococcal resistance—a report from the drug-resistant <i>Streptococcus pneumoniae</i> Working Group. <i>Pediatr Infect Dis J</i>. 1999; 18:1-9. http://www.ncbi.nlm.nih.gov/pubmed/9951971?dopt=AbstractPlus</p><p>303. Blumer JL. Pharmacokinetics and pharmacodynamics of new and old antimicrobial agents for acute otitis media. <i>Pediatr Infect Dis J</i>. 1998; 17:1070-5. http://www.ncbi.nlm.nih.gov/pubmed/9850001?dopt=AbstractPlus</p><p>304. Jacobs MR. Antibiotic-resistant <i>Streptococcus pneumoniae</i> in acute otitis media: overview and update. <i>Pediatr Infect Dis J</i>. 1998; 17:947-52. http://www.ncbi.nlm.nih.gov/pubmed/9802651?dopt=AbstractPlus</p><p>305. Poole MD. Implications of drug-resistant <i>Streptococcus pneumoniae</i> for otitis media. <i>Pediatr Infect Dis J</i>. 1998; 17:953-6. http://www.ncbi.nlm.nih.gov/pubmed/9802652?dopt=AbstractPlus</p><p>306. Adachi JA, Ostrosky-Zeichner L, Dupont HL et al. Empirical antimicrobial therapy for travelers’ diarrhea. <i>Clin Intect Dis</i>. 2000; 31:1079-83.</p><p>307. Onderstepoort J. The antibiotic sensitivity patterns of Bacillus anthracis isolated from Kruger National Park. <i>J Vet Res</i>. 1991; 58:17-9.</p><p>308. Inglesby TV, Henderson DA, Bartlett JG et al. Anthrax as a biologic weapon: medical and public health management. <i>JAMA</i>. 1999; 281:1735–45. http://www.ncbi.nlm.nih.gov/pubmed/10328075?dopt=AbstractPlus</p><p>309. Inglesby TV, Dennis DT, Henderson DA for the Working Group on Civilian Biodefense. Plague as a biological weapon: medical and public health management. <i>JAMA</i>. 2000; 283:2281–90. http://www.ncbi.nlm.nih.gov/pubmed/10807389?dopt=AbstractPlus</p><p>310. US Army Medical Research Institute of Infectious Disease. USAMRIID’s medical management of biologic casualties handbook. 4th ed. USAMRIID: Fort Detrick, MD; 2001 Feb.</p><p>311. Butler T, Levin J, Linh NN et al. Yersinia pestis infection in Vietnam: II Quantiative blood cultures and detection of endotoxin in the cerebrospinal fluid of patients with meningitis. <i>J Infect Dis</i>. 1976; 133:493–9. http://www.ncbi.nlm.nih.gov/pubmed/1262715?dopt=AbstractPlus</p><p>312. Dworkin MS, Hanson DL, Kaplan JE et al. Risk for preventable opportunistic infections in persons with AIDS after antiretroviral therapy increases CD4+ T lymphocyte counts above prophylaxis thresholds. <i>J Infect Dis</i>. 2000; 182:611-5. http://www.ncbi.nlm.nih.gov/pubmed/10915098?dopt=AbstractPlus</p><p>313. Mussini C, Pezzotto P, Govoni A et al. Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficient virus type 1-infected patients: the changes in opportunistic prophylaxis study. <i>J Infect Dis</i>. 2000; 181:1635-42. http://www.ncbi.nlm.nih.gov/pubmed/10823763?dopt=AbstractPlus</p><p>314. Lopez Bernaldo de Quiros JC, Miro JM, Pena JM et al. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection: Grupo de Estudio del SIDA 04/98. <i>N Engl J Med</i>. 2001; 344:159-67. http://www.ncbi.nlm.nih.gov/pubmed/11172138?dopt=AbstractPlus</p><p>315. Furrer H, Opravil M, Rossi M et al. Discontinuation of primary prophylaxis in HIV-infected patients at high risk of Pneumocystis carinii pneumonia: prospective multicentre study. <i>AIDS</i>. 2001; 15:501-7. http://www.ncbi.nlm.nih.gov/pubmed/11242147?dopt=AbstractPlus</p><p>316. Kirk O, Lundgren JD, Pedersen C et al. Can chemoprophylaxis against opportunistic infections be discontinued after an increase in CD4 cells induced by highly active antiretroviral therapy? <i>AIDS</i>. 1999; 13:1647-51.</p><p>317. Soriano V, Dona C, Rodriguez-Rosado R et al. Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy. <i>AIDS</i>. 2000; 14:383-6. http://www.ncbi.nlm.nih.gov/pubmed/10770540?dopt=AbstractPlus</p><p>318. Ledergerber B, Mocroft A, Reiss P et al. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. <i>N Engl J Med</i>. 2001; 344:168-74. http://www.ncbi.nlm.nih.gov/pubmed/11188837?dopt=AbstractPlus</p><p>319. Furrer H, Opravil M. Bernasconi E et al. Stopping primary prophylaxis in HIV-1-infected patients at high risk of toxoplasma encephalitis: Swiss HIV cohort study. <i>Lancet</i>. 2000; 355:2217-8. http://www.ncbi.nlm.nih.gov/pubmed/10881897?dopt=AbstractPlus</p><p>320. Centers for Disease Control and Prevention. Fact sheet for health professionals, Cyclospora infection: information for health care providers. From CDC website (http://www.cdc.gov/ncidod/dpd/parasites/cyclospora/healthcare_cyclospora.htm)</p><p>321. American Academy of Pediatrics Subcommittee on Management of Acute Otitis Media. Diagnosis and management of acute otitis media. <i>Pediatrics</i>. 2004: 113:1451-65.</p><p>a. Monarch Pharmaceuticals. Septra<sup></sup> tablets, DS (double strength) tablets, suspension, and grape suspension prescribing information. Bristol, TN; 2000 Feb.</p><p>b. AHFS Drug Information 2004. McEvoy GK, ed. Co-trimoxazole. American Society of Health-System Pharmacists; 2004: 420-8.</p><p>c. Stegeman CA, Tervaert JW, de Jonh PE et al. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener’s granulomatosis. <i>N Engl J Med</i>. 1996; 335:16-20. http://www.ncbi.nlm.nih.gov/pubmed/8637536?dopt=AbstractPlus</p><p>d. Guerrant RL, Gilder TV, Steiner TS et al. Practice guidelines for the management of infectious diarrhea. <i>Clin Infect Dis</i>. 2001; 32:331-50. http://www.ncbi.nlm.nih.gov/pubmed/11170940?dopt=AbstractPlus</p><p>e. American Thoracic Society. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. <i>Am J Respir Crit Care Med</i>. 1997; 156:S1-25.</p><p>HID. Trissel LA. Handbook on injectable drugs. 17th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2013:1107-13.</p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>Can I drink alcohol while taking sulfamethoxazole / trimethoprim DS tablets?</li>
<li>What dose of co-trimoxazole is used in a patient with a UTI?</li>
</ul><h2>More about Co-trimoxazole (sulfamethoxazole / trimethoprim)</h2><ul class="more-resources-list more-resources-list-general">
<li>Side Effects</li>
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>3 Reviews</li>
<li>Drug class: sulfonamides</li>
</ul><h3>Consumer resources</h3><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Bacterial Infection</li>
<li>Acne</li>
<li>Bronchitis</li>
<li>Bacterial Skin Infection</li>
<li data-more-config-id="list-data-resources-conditions">... +21 more</li>
</ul><p class="ddc-disclaimer-link">Medical Disclaimer</p></body></html>